Antibody-Drug Conjugates for Cancer Therapy.

1. Introduction

Despite the range of new anti-cancer drugs in the market, there were 9.6 million deaths from cancer globally in 2018, with approximately one in six of all deaths being due to cancer [ 1 ]. A recent review concluded that most of the anti-cancer drugs that entered the market between 2009 and 2013 showed only marginal gains in terms of overall survival and that there is an urgent need to increase therapeutic efficacy [ 2 ]. Systemic therapies based on the use of monoclonal antibodies (mAbs) started to emerge after the discovery of hybridoma technology by Kohler and Milstein in 1975. In 1988, Greg Winter pioneered the technique to humanize monoclonal antibodies and thereafter, therapeutic monoclonal antibodies have been successfully developed for the treatment of various cancers. To date, approximately 30 mAbs have been approved by the US Food and Drug Administration (FDA) for the treatment of cancer. The specificity of mAbs also makes them well suited for the targeted delivery of drugs to cancer cells whilst avoiding normal tissues. Monoclonal antibody technology has been further improved over the next decades by conjugating antibodies with cytotoxic drugs [ 3 ]. Such conjugates, called antibody–drug conjugates (ADCs), are targeted agents that link a cytotoxic drug (also called as cytotoxic payload or warhead) via a linker to a monoclonal antibody which specifically recognizes a cellular surface antigen and deliver toxic payload at the tumor site, thus improving the efficacy of chemotherapy and reducing systemic exposure and toxicity [ 4 ]. More than 80 ADCs are currently under clinical development worldwide [ 5 , 6 ]. In this paper, we provide an overview of the biology and chemistry of ADCs, discuss key components of ADC design and discuss the current status of clinically approved and underdeveloped ADCs. We also discuss resistance mechanisms to ADC, the role of molecular imaging in the clinical development of ADCs and give an opinion on future perspectives.

2. Design and Structure of Antibody–Drug Conjugates

The use of ADCs has evolved over time, becoming increasingly widespread as initial problems were overcome by better target selection, accompanied by improvements in payloads, linker technologies and conjugation techniques ( Figure 1 ).

2.1. Target Selection

Unconjugated mAbs have various mechanisms of action including target receptor neutralization, receptor downregulation, signalling disruption, antibody dependent cell-mediated cytotoxicity (ADCC), complement-dependent cell-mediated cytotoxicity (CDCC) and immune checkpoint inhibition [ 7 , 8 ]. On the other hand, ADCs rely on target receptor internalization to deliver the cytotoxic payload to the cancer cells. Hence, selecting an appropriate target antigen is a critical step for the success of an antibody–drug conjugate.

Ideally, the target antigen should be abundant on the cell surface to be available for binding by the circulating ADC, e.g., melanoma cell lines with p97 receptor expression levels from 80,000 to 280,000 receptors per cell showed sensitivity to ADC L49-vcMMAF, while other cancer cell lines with lower p97 expression were resistant to L49-vcMMAF [ 9 ]. However, various other ADCs have shown efficacy over a wide range of antigen expression levels based on other characteriztics of the target antigen, including binding affinity and rate of internalization. Gemtuzumab ozogamicin has demonstrated efficacy at a relatively low expression of CD33 (5000 to 10,000 receptors per cell) as compared to trastuzumab emtansine (T-DM1) which usually requires high ErbB2 expression levels (>2 million receptors per cell) [ 10 , 11 ]. The high surface expression of the antigen may not lead to ADC efficacy if trafficking into the tumor cell is impaired. Inge et al. [ 12 ] showed that after antibody binding CD21 does not effectively internalize, even when expressed at very high levels, resulting in a lack of efficacy with anti-CD21-MCC-DM1 ADCs. This study also showed that CD21 forms a complex with CD19 on the surface of B cells and prevents internalization of CD19 after it is bound to anti-CD19 antibody and decreasing anti-CD19-MCC-DM1 efficacy [ 12 ].

To minimize off-target toxicity, the target antigen should have exclusive or preferential expression on cancer cells with a minimal expression on healthy tissue. Four out of nine approved ADCs—inotuzumab ozogamicin, gemtuzumab ozogamicin, brentuximab vedotin, and polatuzumab vedotin—target lineage-specific markers that include CD22, CD33, CD30 and CD79, respectively. These antigens have consistent expression across the target cell population. The target antigen should also have minimal secretion in circulation from the cancer cells, as antibodies can bind to these secreted receptors in the circulation, thus limiting the amount of antibody available for target cell binding [ 13 ].

The target antigen should internalize efficiently upon ADC binding to allow the antigen–ADC complex to be internalized via receptor-mediated endocytosis, and it should undergo appropriate intracellular trafficking and degradation, thereby allowing the cytotoxic warhead to be released [ 14 ]. Target antigens on the cell surface can have variable rates for basal and antibody induced internalization which can affect ADC efficacy [ 12 ]. For example, CD74 antigen is rapidly internalized into target cells following antibody binding. The preclinical data for anti-CD74 ADC immu-110 showed similar efficacy to other ADCs that target slower internalizing antigens with more potent cytotoxic payloads [ 15 ]. Inadequate or inefficient internalization increases the chance of toxicity from inappropriate payload delivery outside the cancer cell [ 16 ]. Other factors which influence antigen–ADC internalization are binding epitope on target antigen and the affinity of the ADC to the antigen [ 10 ].

Lastly, antigens that are abundant in the circulation should also be avoided to prevent sequestration and/or degradation of the ADC in the circulation. More than 50 different known antigens have been used as targets in ADCs currently in preclinical or clinical development ( Table 1 ).

2.2. Choice of Antibody

The selection of an appropriate antibody for ADC is also important and can have a significant impact on efficacy, pharmacokinetic/pharmacodynamic profiles and therapeutic index. An ideal mAb for an ADC should be target specific with strong target binding affinity. In addition, it should have low immunogenicity, low cross-reactivity, efficient internalization and long plasma half-life [ 17 , 18 ]. Antibodies in human beings can be classified into five main classes: IgA, IgD, IgE, IgG, and IgM. These closely related immunoglobulins are composed of 82–96% protein and 4–18% carbohydrate; they differ in heavy chain structure and have distinct effector function. IgA is further subclassified into IgA1 and IgA2. IgG has been subdivided into IgG1, IgG2, IgG3 and IgG4. Due to its favourable characteriztics, scientists have focused on IgG class for therapeutics. An IgG antibody consists of two heavy chains and two light chains. It has two antigen binding fragments (Fabs) which mediate antigen recognition and a constant fragment (Fc), which mediates the binding of the antibody with effector cells of the immune system. The Fc fragment also regulates the half-life of the antibody in circulation through its interaction with FcRn (the neonatal Fc receptor for IgG) [ 19 , 20 ]. The IgG1 subtype is frequently used in antibody therapeutics due it its serum stability and strong binding affinity for Fc receptor. However, an increasing number of ADCs are based on Fc-silent mAbs and the suitability of Fc for an ADC is determined on a case by case basis [ 8 , 19 , 21 , 22 , 23 , 24 ]. However, Fcγ binding can also lead to undesirable adverse events. T-DM1 binds to FcγRIIa and internalized by megakaryocytes resulting in thrombocytopenia [ 25 ]. Another ADC, LOP628 consisting of c-Kit IgG1 antibody conjugated to maytansine, was found to induce hypersensitivity reactions in patients in a phase I trial after mast cell degranulation due to FcγR1 and FcγRII binding on mast cells [ 26 ]. Further development of LOP628 ADC has been discontinued. IgG2 and IgG4 have reduced capacity to activate the complement cascade. TR 1801-ADC, an ADC where a c-Met IgG2 antibody is used as a backbone, is currently in phase I clinical trial (Table 3). IgG4 is preferred for the development of ADCs when recruitment of host effector function is least required. However, despite a lower affinity for FcγR compared with IgG1, in its non-fucosylated form, IgG4 antibody is able to bind to FcγRIIIa [ 25 ]. IgG4 antibodies have been used in the development of gemtuzumab ozogamicin and inotuzumab ozogamicin ( Table 2 ).

Early ADCs utilized murine antibodies which were highly immunogenic, resulting in reduced efficacy and toxicity due to the development of human anti-murine antibodies (HAMAs) [ 27 , 28 ]. To overcome this problem, chimeric, humanized or fully human antibodies were used in next-generation ADCs. A chimeric antibody contains the mouse antigen binding fragments (Fabs) linked to a human constant fragment (Fc). The human constant fragment mediates interaction with cells of the immune system, and hence immunogenicity is reduced. ADCs that contains chimeric antibodies are brentuximab vedotin and indatuximab ravtansine ( Table 2 and Table 3 ). However, human anti-chimeric antibodies (HACA) could still develop in these patients. In contrast, a humanized antibody contains only the complementarity determining regions of Fab that are grafted into the human Fab regions and hence the risk of human anti-human antibodies (HAHA) is reduced even further. An example of humanized antibody in ADC trastuzumab emtansine is mAb trastuzumab, linked to cytotoxic payload DM1 [ 29 ]. The benefit of using a fully human antibody is to prevent mounting an immune response against these antibodies. Enfortumab vedotin is an ADC consisting of fully human anti-nectin-4 mAb which was recently approved by the FDA for management of patients with advanced urothelial cancer ( Table 2 ).

2.3. Cytotoxic Payload

The first ADCs utilized readily available conventional cytotoxics such as doxorubicin (e.g., BR96-doxorubicin), methotrexate, mitomycin, fluorouracil and vinca alkaloids [ 30 , 31 , 32 , 33 ]. These chemotherapeutic drugs have relatively low potency with half maximal inhibitory concentration (IC 50 ) values in the micromolar range, they lacked selectivity and their accumulation in target cells was poor. As a result, this contributed to the relatively low efficacy of these early ADCs [ 34 , 35 ].

Subsequently, more potent payloads have been utilized with IC 50 values in the subnanomolar range. In addition to potency, plasma stability, low immunogenicity, small molecular weight and a long half-life are also desirable characteriztics for ADC payloads [ 36 ]. It was also important that the chemistry of payload should not disrupt the internalization properties of the parental mAb. The most commonly used payloads currently mainly target either DNA or tubulins.

DNA targeting payloads include calicheamicins, duocarmycins, pyrrolobenzodiazepines (PBDs), SN-38 and DXd. Calicheamicins in ADCs inotuzumab ozogamicin and gemtuzumab ozogamicin bind to a minor groove of DNA and induce double-stranded breaks and subsequent cell apoptosis [ 37 ]. As duocarmycin is rapidly degraded in plasma, it is incorporated into ADCs in its inactive pro-drug form, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA). Once released inside cells, duocarmycin is attached to the minor groove of DNA in A-T-rich region and causes DNA alkylation, resulting in DNA damage in both dividing and non-dividing cells and ultimately cell death. Duocarmycin is the cytotoxic payload in trastuzumab duocarmazine currently in phase II/III clinical trials [ 38 , 39 ]. The pyrrole[2,1-c] [ 1 , 4 ] benzodiazepines (PBDs) cause DNA alkylation. The naturally occurring PBDs produced by actinomycetes Streptomyces and Micrococcus (e.g., anthramycin) form single alkylated DNA adducts by binding to guanine residues in the DNA minor groove. However, the synthetic PBD dimers consisting of two PBD units joined through a linker can also form interstrand or intrastrand DNA cross-links. PBD dimers are sequence selective, and are distinguished from conventional DNA cross-linking agents (e.g., platinum drugs), in that the interstrand cross-links formed between DNA and PBD dimer do not cause distortion of DNA and hence go undetected by DNA repair mechanisms, maintaining its activity and ultimately leading to cell death [ 40 , 41 , 42 ]. Loncastuximab tesirine is an ADC containing anti-CD19 antibody conjugated to a PBD dimer SG3199, and is currently in a phase III clinical trial ( Table 3 ) [ 42 ]. SN-38 is an active metabolite of irinotecan. Irinotecan is a topoisomerase I inhibitor that interrupts DNA replication with subsequent cell cycle arrest and cell death. SN-38 is the cytotoxic payload in ADC sacituzumab govitecan [ 43 ]. DXd, an exatecan derivative (DX-8951 derivative) is also a topoisomerase I inhibitor. It is ten times more potent than SN-38 [ 44 ]. It is used as a payload in a trastuzumab deruxtecan which was recently approved by the FDA for treatment of metastatic breast cancer [ 45 ].

The anti-tubulin agents include auristatins and maytansinoids. Auristatins are synthetic analogues of natural agent dolastatin 10, which was first isolated from sea hare Dolabella Auricularia in 1987 [ 46 ]. They disrupt microtubules and induce cell cycle arrest in the G2/M phase. Four out of nine approved ADCs use auristatins as payloads. Monomethyl auristatin E (MMAE) is used as a warhead in approved ADCs brentuximab vedotin, polatuzumab vedotin and enfortumab vedotin while monomethyl auristatin F (MMAF) was used in depatuxizumab mafodotin. Further development of depatuxizumab mafodotin has been ceased owing to disappointing results in a phase III trial [ 47 , 48 , 49 , 50 ]. Maytansinoids are derived from the naturally occurring maytansine, which was originally isolated from the bark of the shrub Maytenus ovatus [ 51 ]. Maytansine binds tubulin at the vinca-binding site, inhibit depolymerization and induce mitotic arrest [ 52 ]. The synthetic maytansinoid derivative mertansine (DM1) is the payload in approved ADCs trastuzumab emtansine and brentuximab vedotin while DM4 is conjugated to coltuximab ravtansine. Coltuximab ravtansine is in phase I/II clinical trials. They all have shown potent cytotoxic activity [ 53 , 54 , 55 ].

2.4. Linkers

The linkers play a significant role in antibody–drug conjugate design as they link the cytotoxic payload to the antibody. Various factors such as linker chemistry, mode and the site of conjugation play a crucial role in the pharmacokinetic and pharmacodynamic properties of ADC. Linkers must maintain the stability of the ADC in the blood circulation to enable it to reach the cancer cell intact but must then be readily cleaved when internalized so that the payload can be released. Broadly speaking, linkers can be categorized into two groups: cleavable or non-cleavable linkers.

Cleavable linkers depend on physiological conditions in the cell to cleave the linker and can be further subdivided into acid sensitive, protease sensitive or glutathione sensitive. The acid-sensitive linker AcBut (4-4′-acetylphenoxy butanoic acid) is used to link anti-CD33 and anti-CD22 antibodies to calicheamicin in ADCs gemtuzumab ozogamicin and inotuzumab ozogamicin, respectively. This linker connecting the antibody to calicheamicin forms a hydrazone with the hydrazide of the calicheamicin derivative, which is hydrolysed in lysosomal pH, and calicheamicin is released, leading to cell death. However, the acid-sensitive linker has a low plasma stability of 48–72 h [ 56 , 57 , 58 ]. The protease-cleavable linker, e.g., dipeptide valine-citrulline (Val-Cit, V-C), is utilized in brentuximab vedotin to link the monomethylauristatin E (MMAE) payload to the anti-CD30 antibody. Val-Cit is more stable in the plasma due to the presence of protease inhibitors than acid-based linkers, but can still be rapidly hydrolysed by lysosomal enzyme cathepsin B once internalized [ 55 ]. Another protease-cleavable valine-alanine (Val-Ala) linker has been used for multiple ADCs, including TR1801 where PBD is conjugated to an anti-cMET antibody [ 59 ]. Lastly, glutathione-sensitive disulfide linkers are commonly used in ADC design. Glutathione is released during cell survival and tumor growth. A high concentration of glutathione is found in the intracellular compartment in cancer cells as compared to normal cells [ 60 ]. Therefore, glutathione-sensitive linkers are stable in blood circulation and are cleaved by elevated glutathione in the tumor cells, releasing the cytotoxic payload. The ADC mirvetuximab soravtansine (IMGN 853) is comprised of FRα binding mAb M9346A via a glutathione-sensitive cleavable disulfide SPDB linker attached to cytotoxic payload DM4 [ 61 ].

The second major category of linkers is non-cleavable linkers. Non-cleavable linkers form non-reducible bonds with the amino acid residues of the mAb and should therefore be more stable in the bloodstream, have longer half-lives and reduced off target toxicity. ADCs involving non-cleavable thioether linkers are efficiently internalized in cells and then degraded in lysosomes to yield metabolites consisting of intact cytotoxic payload and the linker attached to amino acid lysine [ 62 ]. T-DM1 has been successfully created by a non-cleavable thioether linker ( N -succinimidyl-4-( N -maleimidomethyl) cyclohexane-1-carboxylate; SMCC attached to anti-ErbB2 antibody trastuzumab and cytotoxic maytansinoid payload DM1 [ 63 ]. In Belantamab mafodotin, the anti-BCMA antibody has been conjugated to MMAF via a non-cleavable protease-resistant maleimidocaproyl (mc) linker [ 64 ].

2.5. Antibody–Drug Conjugation

The conjugation of antibody and the cytotoxic payload can alter the pharmacokinetics and therapeutic index of antibody–drug conjugates. The conventional drug conjugation usually occurs on the mAb backbone either via alkylation or acylation of lysine sidechains as used in gemtuzumab ozogamicin and trastuzumab emtansine or via reduction of disulfide bonds that can liberate cysteine residues to be attached to linkers as utilized in brentuximab vedotin ( Figure 1 ) [ 65 ]. These conventional drug conjugation strategies are random and can produce a heterogeneous mixture of ADCs with a different number of drugs to antibody ratio (DAR) leading to variable pharmacokinetics, efficacy and safety profiles [ 65 , 66 ]. The DAR may vary between zero and eight cytotoxic payloads per antibody. Although high DAR can produce more potent ADCs, it can also result in destabilization, aggregation, increased off-target toxicity, and enhanced drug clearance from systemic circulation [ 67 , 68 ]. Hence, there is more interest in site-specific conjugation (SSC) that can produce more homogenous ADCs. These strategies include insertion of engineered cysteine residues, insertion of unnatural amino acids in the antibody sequence or enzymatic conjugation through glycotransferases and transglutaminases [ 66 , 69 , 70 , 71 ]. Some ADCs with site-specific conjugation in phase I clinical trials are MEDI2228, PF-06804103 and TR1801-ADC ( Table 3 ) [ 72 ].

3. Mechanism of Action of ADC

ADCs have poor oral bioavailability and are administered intravenously to prevent degradation by digestive enzymes. After binding to its target, the ADC–antigen complex is typically internalized via clathrin- or caveolae-mediated endocytosis or via pinocytosis [ 73 ]. Internalization results in inward budding of the cell membrane to form an early endosome ( Figure 2 ) [ 74 ]. Early endosomes mature into late endosomes before fusing with lysosomes. For ADCs with cleavable linkers, the cleavage mechanisms (e.g., hydrolysis, proteolytic cleavage or reductive cleavage) occur in early or late endosomes; however, ADCs with non-cleavable linkers require complex proteolytic cleavage in lysosomes by cathepsin B and plasmin [ 74 ]. After cleavage, the cytotoxic payload is released from lysosomes into the cytoplasm. The cytotoxic payloads either target DNA and induce single- or double-stranded DNA breaks or disrupt microtubules, resulting in apoptosis or other means of cell death [ 75 ]. It is worth mentioning that ATP-dependent proton pumps in early endosomes establish an acidic environment that creates an interaction between the mAb component of the ADC and the human neonatal Fc receptor (FcRns). ADCs bound to FcRns are recycled back to the cell surface where a physiologic pH of 7.4 releases ADCs from the FcRn. This recycling mechanism prevents normal cell death in the event of misdelivery and prolongs the half-life of antibodies [ 19 ].

Some ADCs also act by bystander killing. Bystander killing occurs when neighbouring cells which themselves may not express target antigen are killed by cytotoxic payloads. These cytotoxic payloads are either expelled from cells that express the ADC target antigen following internalization and degradation of the ADC or are released within the tumor microenvironment and do not require ADC internalization. Bystander killing depends on various factors including the extent of ADC internalization, presence of cleavable or non-cleavable linker and properties of cytotoxic payloads [ 76 ]. Some ADCs also activate the complement system via antibody dependent cellular toxicity (ADCC), complement-dependent cytotoxicity (CDC) or antibody dependent cellular phagocytosis (ADCP), resulting in infiltration of tumors by immune cells [ 77 , 78 , 79 ].

4. Clinically Approved ADCs

A total of nine ADCs have so far received regulatory approval by the FDA for use in the USA and four ADCs have been approved by the European Medicines Agency (EMA) ( Table 2 ).

4.1. Brentuximab Vedotin

Brentuximab vedotin (SGN-35, Adcetris) is an antibody–drug conjugate composed of an anti-CD30 monoclonal antibody linked to tubulin inhibitor MMAE. It not only exerts its anti-cancer activity by binding directly to CD30+ lymphocytes but also has other mechanisms of action including antibody dependent cellular phagocytosis and bystander killing [ 55 ].

Brentuximab vedotin (BV) received accelerated FDA approval in 2011 for relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL). ALCL is an aggressive subtype of T cell lymphoma characterized by the uniform expression of CD30. FDA approval was based on a single-arm phase II study when BV induced objective response (OR) in 86% of patients and complete remission (CR) in 57% of patients with relapsed or refractory systemic ALCL after at least one prior therapy [ 80 ]. BV is also approved for the treatment of relapsed or refractory Hodgkin’s lymphoma. A meta-analysis of six studies determined an OR of 61% and a CR of 38% as a single agent [ 81 ]. BV is also effective when administered in combination with other chemotherapeutic agents. In a single-arm phase I/II study, when administered with bendamustine, BV demonstrated a higher OR of 92.5% and a CR of 73.6% in patients with relapsed or refractory Hodgkin’s lymphoma [ 82 ]. Brentuximab vedotin has also shown activity in CD30+ peripheral T cell lymphoma (PTCL). In a phase II study, single-agent BV had an OR of 41% and a CR of 24% in patients with relapsed/refractory CD30+ PTCL [ 83 ]. In 2017, BV received FDA approval for treatment of patients with refractory primary cutaneous ALL or CD30+ mycosis fungoides based on a phase III ALCANZA trial that showed an OR of 56.3% that lasted for at least four months vs. 12.5%, resulting in a between-group difference of 43.8% [95% confidence interval (CI) 29.1–58.4; p < 0.0001]. In this phase III study, patients were randomized 1:1 to receive BV or treatment of physician’s choice (oral methotrexate, oral bexarotene) for up to 48 weeks [ 84 ]. In 2018, brentuximab vedotin was approved for the treatment of patients with previously untreated stage III or IV classical Hodgkin’s lymphoma in combination with chemotherapy and in patients with previously untreated systemic ALCL or CD30+ PTCLs based on ECHELON-1 and ECHELON-2 trials [ 85 , 86 ]. In ECHELON-1 phase III trial, patients with treatment-naïve stage III or stage IV Hodgkin’s lymphoma were assigned to receive either BV, doxorubicin, vinblastine and dacarbazine (A+AVD) or doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The 2 year progression-free survival (PFS) rates in A+AVD and ABVD groups were 82.1% versus (vs.) 77.2% [Hazard ratio (HR) 0.77, 95% CI 0.60–0.98; p = 0.04). The interim 2 year overall survival rates for A+AVD vs. ABVD were 96.6% vs. 94.2% (HR 0.73, 95% CI, 0.45–1.18; p = 0.20) [ 85 ]. In ECHELON-2 phase III trial, treatment-naïve CD30+ PTCL patients were randomly assigned to receive either BV, cyclophosphamide, doxorubicin and prednisolone (A+CHP) or cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP). The median progression-free survival (mPFS) in the BV group was 48.2 months vs. 20.8 months in the CHOP group (HR 0.71, 95% CI 0.54–0.93, p = 0.0110). The median overall survival was not reached for both groups. However, improvements in overall survival were noted (HR 0.66, 95% CI 0.46–0.95, p = 0.024) [ 86 ]. Toxicities with BV include infusion reactions, myelosuppression, gastrointestinal haemorrhage, perforation, acute pancreatitis, progressive multifocal leukoencephalopathy and peripheral sensory neuropathy [ 80 , 87 , 88 ].

Currently, brentuximab vedotin is being investigated in 83 active phase I–III clinical trials registered on ClinicalTrials.gov in various haematological malignancies in different treatment combinations. Clinical trials worth mentioning are in relapsed or refractory Hodgkin’s lymphoma as an alternative to autologous stem cell transplant (NCT0347133), treatment-naïve Hodgkin’s lymphoma along with chemotherapy vs. immunotherapy ( NCT03907488 ), and diffuse large B cell lymphoma along with lenalidomide and rituximab ( NCT04404283 ).

4.2. Trastuzumab Emtansine

Trastuzumab emtansine (T-DM1, Kadcyla) is an ADC, in which anti-ErbB2 (also called anti-HER2) monoclonal antibody trastuzumab is conjugated to microtubule inhibitor DM1 [ 89 ].

The pivotal phase III EMELIA trial which led to FDA approval of T-DM1 in 2013 showed an improved mPFS of 9.6 months with T-DM1 vs. 6 months with lapatinib plus capecitabine (HR 0.65, 95% CI 0.55–0.77; p < 0.001) and median overall survival (mOS) of 30.9 vs. 25.1 months (HR 0.68, 95% CI 0.55–0.85; p < 0.001) in patients with ErbB2-positive advanced breast cancer previously treated with trastuzumab and a taxane [ 29 , 54 ]. T-DM1 was compared with the treatment of physician’s choice in another phase III TH3RESA study in ErbB2-positive advanced breast cancer patients previously treated with two or more ErbB2-directed regimens, including trastuzumab. This trial showed an improved mPFS of 6.2 vs. 3.3 months (HR 0.53, 95% CI 0.42–0.66; p < 0.0001) and a mOS of 22.7 vs. 15.8 months (HR 0.68, 95% CI 0.54–0.85; p = 0.0007) [ 90 ]. The most common adverse events in patients receiving T-DM1 are fatigue, nausea, musculoskeletal pain, thrombocytopenia and constipation [ 54 ].

At present, T-DM1 is under investigation in 36 active phase I–III clinical trials registered on ClinicalTrials.gov in ErbB2-positive breast cancer, lung cancer, colorectal cancer and other solid tumors in various combinations. T-DM1 along with either tucatinib, palbociclib or afatinib is being investigated in advanced ErbB2-positive breast cancer patients ( NCT03975647 , NCT03560696, and NCT04158947 ). T-DM1 with osimertinib is being evaluated in EGFR mutant lung cancer ( NCT03784599 ) and T-DM1 monotherapy is being tested in advanced ErbB2-positive colorectal cancer patients progressing after trastuzumab and lapatinib ( NCT03418558 ).

4.3. Inotuzumab Ozogamicin

Inotuzumab ozogamicin (Besponsa) is an ADC composed of anti-CD22 monoclonal antibody linked to a semi-synthetic derivative of calicheamicin Calich-DMH. Calicheamicin is a DNA-damaging cytotoxic agent derived from soil bacterium Micromonospora echinospora [ 58 ].

In 2017, Inotuzumab ozogamicin (InO) gained FDA approval for treatment of relapsed or refractory CD22+ acute lymphoblastic leukaemia (ALL), based on phase III clinical trial INO-VATE ALL, that showed significant improvement in mPFS (5.0 vs. 1.8 months, HR 0.45, 95% CI 0.34–0.61; p < 0.001) and mOS (7.7 vs. 6.7 months, HR 0.77, 95% CI 0.58–1.03, p = 0.04) with InO as compared to investigator’s choice standard intensive chemotherapy [ 37 ]. The most commonly observed adverse events with inotuzumab ozogamicin are myelosuppression, increased transaminases, headache, nausea and fatigue [ 37 ]. It is also associated with fatal and life-threatening sinusoidal obstruction syndrome also called veno-occlusive disease, which occurred in patients with relapsed or refractory ALL who underwent haematopoietic stem cell transplant (HSCT) after inotuzumab ozogamicin treatment [ 37 , 91 ].

Investigators are eagerly awaiting results of 19 active phase I–III clinical trials registered on ClinicalTrials.gov that are testing inotuzumab ozogamicin in acute lymphoblastic leukaemias, including evaluating InO in the first-line setting along with chemotherapy ( NCT03150693 ), with blinatumomab in B lineage ALL ( NCT03739814 ) and comparing different dosing schedules ( NCT03677596 ).

4.4. Gemtuzumab Ozogamicin

Gemtuzumab ozogamicin (Mylotarg) is an anti-CD33 antibody conjugated with calicheamicin derivative (N-acetyl gamma-calicheamicin-dimethyl hydrazide) payload.

In 2000, gemtuzumab ozogamicin (GO) gained FDA accelerated approval for treatment of CD 33+ acute myeloid leukaemia (AML) [ 92 ]. However, GO was withdrawn from the market afterwards when post-marketing trials showed that it did not improve survival and was associated with significant toxicities including fatal anaphylaxis, adult respiratory distress syndrome and veno-occlusive disease [ 92 , 93 ]. In 2017, gemtuzumab ozogamicin was reapproved from the FDA based on new data showing efficacy at a lower dose and fractionated dosing schedule. In the ALFA-0701 study, a phase III trial undertaken in patients with untreated AML, 140 patients were assigned to low fractionated-dose GO added to standard first-line chemotherapy (daunorubicin and cytarabine) group, and 140 patients were assigned to receive standard first-line chemotherapy (daunorubicin and cytarabine). Median overall survival was significantly better in patients who received GO as compared to the control group who only received standard treatment (34 vs. 19.2 months, HR 0.69, 95% CI 0.49–0.98; p = 0.0368) [ 94 ]. Grade 3 and 4 adverse haematological and non-haematological adverse events were increased in patients who were treated with GO, without an increase in the risk of death from toxicity [ 94 ]. In another phase III clinical trial, GO significantly improved mOS (4.9 vs. 3.6 months, HR 0.69, 95% CI 0.53–0.90; p = 0.005) when compared with best supportive care in older patients with newly diagnosed AML [ 95 ]. In this study, the rates of serious adverse events were similar in both groups, and no excess mortality was observed with GO [ 95 ].

Currently, there are 31 active phase I–III clinical trials registered on ClinicalTrials.gov investigating gemtuzumab ozogamicin in AML, acute promyelocytic leukaemia and myelodysplastic syndromes in various dosing schedules and along with other chemotherapy combinations.

4.5. Polatuzumab Vedotin

Polatuzumab vedotin (Polivy) is an ADC composed of an anti-CD79b monoclonal antibody linked to tubulin inhibitor MMAE.

In a multicenter phase Ib/II clinical trial among patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), addition of polatuzumab vedotin to anti-CD 20 antibody rituximab and chemotherapy bendamustine showed improved mPFS (9.5 vs. 3.7 months, HR 0.36, 95% CI 0.21–0.63; p < 0.001) and mOS (12.4 vs. 4.7 months, HR 0.42, 95% CI 0.24–0.75; p = 0.002) [ 48 ]. Polatuzumab vedotin received accelerated approval from the FDA in 2019 for treatment of relapsed or refractory DLBCL. The most common side effects noted with polatuzumab vedotin are myelosuppression, peripheral neuropathy. Polatuzumab vedotin has also been associated with progressive multifocal leukoencephalopathy (PML) [ 48 ].

At present, polatuzumab vedotin is under investigation in eight active phase I–III clinical trials registered on ClinicalTrials.gov in haematological malignancies. These studies are further investigating polatuzumab vedotin for the treatment of Hodgkin’s lymphoma ( NCT04491370 ), first-line treatment for DLBCL ( NCT02611323 , NCT04231877 ), first-line treatment for double- or triple-hit lymphoma ( NCT04479267 ), and chronic lymphocytic leukaemia ( NCT01290549 ).

4.6. Trastuzumab Deruxtecan

Trastuzumab deruxtecan (DS-8201a, Enhertu) is an ADC, composed of an anti-ErbB2 monoclonal antibody, with the same amino acid sequence as trastuzumab, conjugated DXd (DX-8951 derivative). Trastuzumab deruxtecan has a higher drug to antibody ratio as compared to T-DM1 (8 vs. 3 to 4) [ 45 ].

In a multicenter single-arm phase II study of patients with previously treated ErbB2-positive metastatic breast cancer, trastuzumab deruxtecan showed OR in 60.9% of patients with a mPFS of 16.4 months (95% CI, 12.7–not reached) [ 45 ]. Trastuzumab deruxtecan was approved by the FDA in 2019, for treatment of ErbB2+ advanced breast cancer patients who have received prior ErbB2-directed therapies in the metastatic setting. The most common toxicities noted were myelosuppression and nausea. Trastuzumab deruxtecan was also associated with interstitial lung disease [ 45 ].

Currently, trastuzumab deruxtecan is under investigation in 15 active phase I–III clinical trials registered on ClinicalTrials.gov in various solid organ malignancies including ErbB2-expressing non-small-cell lung cancer ( NCT03505710 ), ErbB2 low breast cancer ( NCT03734029 ), ErbB2-positive gastric cancer ( NCT04014075 ) and with immunotherapy combination nivolumab in advanced breast and urothelial cancers ( NCT03523572 ).

4.7. Enfortumab Vedotin

Enfortumab vedotin (ASG-22ME, Padcev) is an ADC composed of nectin-4-directed monoclonal antibody with tubulin inhibitor cytotoxic payload MMAE [ 49 ].

Enfortumab vedotin (EV) received accelerated approval from the FDA in December 2019 for treatment of patients with relapsed or refractory locally advanced or metastatic urothelial cancer. It was the first ADC directed against nectin-4 to receive FDA approval. FDA approval was based on a pivotal single-arm phase II clinical trial in patients with advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor. The trial showed an OR of 44% and a CR of 12%, with a mPFS of 5.8 months and a mOS of 11.7 months [ 96 ]. The main toxicities associated with enfortumab vedotin are fatigue, alopecia, decreased appetite and peripheral sensory neuropathy. Febrile neutropenia was the most common serious adverse event [ 96 ].

Currently, enfortumab vedotin is under investigation in seven active phase I–III clinical trials registered on ClinicalTrials.gov. Enfortumab vedotin is compared to chemotherapy in a phase 1 clinical trial ( NCT03474107 ) in patients with advanced urothelial cancer. The combination of enfortumab vedotin and immunotherapy pembrolizumab is also being evaluated in another phase III clinical trial ( NCT04223856 ) in patients with advanced urothelial cancer. EV is also being tested in other solid organ tumors that express nectin-4 ( NCT02091999 ).

4.8. Sacituzumab Govitecan

Sacituzumab govitecan (IMMU-132, Trodelvy) is an ADC that targets tumor-associated calcium signal transducer 2 (TROP-2) for the selective delivery of SN-38 [ 43 ].

It has been recently approved for patients with metastatic triple-negative breast cancer (mTNBC), who have received at least two systemic therapies for metastatic disease. In a single-arm phase I/II trial of mTNBC patients, sacituzumab govitecan resulted in an OR of 33.3% (3 complete and 33 partial responses), with a mPFS of 5.5 months and a mOS of 13 months [ 97 ]. The most common adverse events noted with this ADC are myelosuppression and diarrhoea [ 97 ].

Currently, sacituzumab govitecan is under investigation in seven active phase I–III clinical trials registered on ClinicalTrials.gov. Sacituzumab govitecan is being evaluated in endometrial cancer ( NCT04251416 ), in patients with glioblastoma ( NCT03995706 ) and in patients with urothelial cancer ( NCT03547973 ). Sacituzumab govitecan and pembrolizumab combination is under investigation in hormone receptor-positive and ErbB2-negative advanced breast cancer ( NCT04448886 ), and in advanced TNBC ( NCT04468061 ). It’s combination with talazoparib ( NCT04039230 ) is being tested in metastatic breast cancer patients.

4.9. Belantamab Mafodotin

Belantamab mafodotin (GSK2857916, Blenrep) is an ADC that targets BCMA, a cell surface B cell maturation antigen expressed on multiple myeloma cells [ 98 ]. BCMA promotes growth and survival of plasma cells, and its serum levels correlate with response to therapy and overall survival in patients with multiple myeloma [ 99 ].

Belantamab mafodotin has received recent FDA approval as a monotherapy treatment for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent. FDA approval was based on the phase II DREAMM-2 study. In this two-arm study, heavily pretreated patients with multiple myeloma received 2.5 or 3.4 mg/kg of belantamab mafodotin every three weeks. The overall response rate was 31% (97.5% CI 20.8–42.6) in patients in the 2.5 mg/kg cohort and 34% (97.5% CI 23.9–46.0) in patients in the 3.4 mg/kg cohort. The most common adverse events reported were keratopathy, decreased visual acuity blurred vision, infusion-related reactions, anaemia and thrombocytopenia [ 100 ].

Belantamab mafodotin is currently being evaluated in five active phase I–III clinical trials registered on ClinicalTrials.gov in multiple myeloma. It is under investigation as monotherapy ( NCT04126200 ), with chemotherapy ( NCT04162210 ), with or without VRd bortezomib, lenalidomide and dexamethasone ( NCT04091126 ) and with proteasome inhibitor bortezomib ( NCT04246047 ).

5. Promising ADCs in Clinical Development

Despite the approval of only nine ADCs, there has been significant improvement in ADC design. At present, there are more than 80 ADCs under clinical development worldwide ( Table 3 ) [ 5 , 6 ]. ADCs are at a frontier for the next generation of systemic therapeutic options for cancer patients. Lessons learned from clinical development of approved ADCs are informing scientists and clinicians for the selection of appropriate target antigens, monoclonal antibodies, liners and cytotoxic payloads.

6. Mechanisms of Resistance to Antibody–Drug Conjugate Therapies

As with all anti-cancer therapeutics, resistance is a significant problem with the use of ADCs. The mechanisms of resistance to ADCs are complex and are influenced by various factors, either arising from each component of the ADC or from a pathway of the mechanism of action of ADCs ( Figure 3 ) [ 153 ]. One major class of resistance mechanisms affects drug delivery. Binding of the ADC to the target antigen may be hampered by downregulation of antigen, loss of antigen expression or mutations in the antigen affecting its recognition by monoclonal antibody. Reduced ErbB2 expression has been identified as an acquired mechanism of resistance to T-DM1 in T-DM1 resistance cell lines [ 154 ]. Loss of CD30 antigen expression has been reported as the cause of resistance to brentuximab vedotin in a patient with anaplastic large-cell lymphoma [ 155 ]. Presence of ligands for antigens can also cause resistance to ADC. Neuregulin is a ligand for ErbB3, and its presence leads to ErbB2 and ErbB3 heterodimerization, resulting in reduced cytotoxicity of T-DMI in breast cancer cell lines [ 156 ]. After binding to the target antigen, the ADC–antigen complex is internalized via clathrin- or caveolae-mediated endocytosis or via pinocytosis [ 73 ]. This internalization process can be altered by defects in the internalization pathway and reduced cell surface trafficking. T-DM1-resistant N87 cells internalize ADCs into intracellular caveolin and alter their trafficking to the lysosomes. T-DM1 colocalization into intracellular caveolin-positive puncta correlated with reduced response to T-DM1 in a panel of ErbB2-positive cell lines [ 157 ]. Once inside cells, degradation of ADCs in lysosomes may be impaired by reduced lysosomal proteolytic or acidification function, resulting in failure of cleavage of cytotoxic payload from ADCs. Cell lines resistant to T-DM1 have shown increased lysosomal pH, leading to decreased proteolytic activity and accumulation of T-DM1 in lysosomes [ 158 ]. Loss of lysosomal transporter expression, e.g., SLC46A3, can inhibit the release of cytotoxic payload from lysosomes to the cytoplasm. Loss of SLC46A3 expression has been reported as a mechanism of innate and acquired resistance to PBD and DM1 bearing ADCs [ 159 ].

Inside the cytoplasm, the expression of the mitotic polo-like kinase 1 (PLK1) has been reported to confer T-DM1 resistance by completing mitosis despite the presence of an abnormal mitotic spindle and thus avoiding mitotic catastrophe by preventing cyclin-dependent kinase 1 (CDK1) activation. Reduced induction of CDK1 results in an inability to halt cell cycle progression [ 160 ]. T-DM1 treatment can increase cyclin B1 expression, leading to cell cycle arrest in the G2/M phase, whereas knockdown of cyclin B1 can induce T-DM1 resistance [ 160 , 161 ]. Drug efflux transporters can efflux ADCs from cells, resulting in drug resistance, which is a common mechanism for chemotherapy drug resistance. Drug efflux pumps have been reported for resistance to gemtuzumab ozogamicin, brentuximab vedotin and T-DM1 [ 153 ].

Resistance can also result from acquired or innate insensitivity to the payload. Dysregulation in the apoptotic pathways may also contribute to cancer cell sensitivity to ADCs. For example, the deficient activity of proapoptotic proteins Bak and Bax and the overexpression of antiapoptotic proteins BCl-2 and Bcl-x can confer resistance to gemtuzumab ozogamicin [ 162 , 163 ]. Another mechanism of resistance to ADCs is an effect of ADCs on the cell cycle. Silencing of cyclin B, a cell cycle protein that participates in the G2–M transition, can result in resistance to T-DM1 [ 153 ]. The heterogeneity of target antigens expressed in tumors may also lead to ADC inability to kill low antigen-expressing cells. The issue of tumor antigen heterogeneity and its evolution over time is compounded by the use of archival tissue for screening for ADC treatment eligibility. Assessment of target antigen expression is pivotal in the preclinical and clinical development of ADCs. Molecular imaging of target antigen expression and tracking of drug delivery in vivo are emerging areas of interest for better patient selection and ADC development.

Researchers are working on various strategies to overcome ADC drug resistance. In order to prevent efflux from cells, the cytotoxic payload of ADCs can be changed to toxins that are poor efflux substrates. Trastuzumab deruxtecan containing a DXd cytotoxic payload can overcome T-DM1 resistance in ErbB2-positive metastatic breast cancer patients [ 45 ]. Using a cytotoxic payload with an alternate mechanism of action can also overcome drug resistance. For example, an anti-CD22-NMS249 ADC containing anthracycline as a payload overcame acquired drug resistance in NHL models, that became resistant to anti-CD22 ADC containing MMAE as a cytotoxic payload [ 164 ]. As drug efflux transporters efflux hydrophobic compounds more efficiently than hydrophilic compounds, ADCs can be designed using maleimidyl-based hydrophilic linkers. The maleimidyl-based hydrophilic linker PEG 4 Mal has shown promising activity in preclinical studies in drug-resistant models [ 165 ]. Switching from a non-cleavable linker to a protease-cleavable mc-vc-PAB linker has overcome T-DM1 resistance in preclinical models [ 164 ]. New designs such as bispecific and biparatopic antibodies can increase cellular internalization. MM-302 is a biparatopic ADC which uses the scFv fragment of the monoclonal antibody. Further development of this ADC has now been discontinued owing to disappointing results in a phase II clinical trial for advanced ErbB2-positive breast cancer patients. Various clinical trials are testing a combination of ADCs with immunotherapy to overcome drug resistance and increase clinical response. For example, brentuximab vedotin and nivolumab with or without ipilimumab is in a phase I/II clinical trial NCT01896999 and T-DM1 with pembrolizumab is in a phase I clinical trial NCT03032107 .

7. Role of Molecular Imaging in the Clinical Development of ADCs

The discovery and development of new drugs is challenging, expensive and time consuming. On average, it takes at least 5–10 years to bring a new drug to market and this costs up to US$1 billion [ 166 , 167 ]. Owing to the dimension of investment involved, and the need for a more efficient process of drug development, there is renewed interest in utilizing molecular imaging for preclinical and clinical development of drugs, including ADCs. Molecular imaging allows the development of imaging probes that can identify target expression or can image drug distribution and confirm in vivo target delivery and normal tissue distribution and pharmacokinetics in real time [ 168 ]. Molecular imaging has been successfully used in ADC preclinical studies and in clinical trials in order to determine tumor target expression, drug stability and delivery to the tumor, and interlesional target heterogeneity. These factors are vital in delivering a safe dose while maximizing antitumor effects as well as providing insight into the in vivo properties of these drugs [ 169 , 170 ]. Both SPECT and PET imaging of ADCs have been reported in preclinical and human studies, with the superior resolution and quantitative capabilities of immunoPET showing particular promise [ 171 ]. The majority of immunoPET studies with intact ADCs have utilized Zirconium-89 ( 89 Zr) due to its suitability for radiochemistry and long half-life (T1/2 = 78.4 h) which facilitates optimal imaging of the biodistribution of intact mAbs.

7.1. Preclinical Studies

7.1.1. CD30

Kang et al. [ 172 ] radiolabeled brentuximab vedotin with 89 Zr to enable tracking of BV and determine CD30 expression in three lung cancer models with different levels of CD30 expression. In vitro characterization revealed strong binding affinity between 89 Zr-Df-BV and CD30 in a cell line with high CD30 expression (Kd 2.07 ± 1.86 nM). PET and biodistribution data also showed that CD30 mediated uptake with a peak value of 9.93 ± 2.70% ID/g in the CD30 high-expressing model 24 h post-injection, while CD30 mice had 5.00 ± 1.56% ID/g at 24 h post-injection, demonstrating different signals in tumors with different levels of CD30 expression.

A novel CD30-targeting ADC comprising of an anti-CD30 antibody conjugated to two molecules of lidamycin (LDM) via a non-cleavable linker has been developed [ 173 ]. Anti-CD30-LDM alone or combination with crizotinib has shown significant anti-tumor activity in a CD30+/ALK+ anaplastic large-cell lymphoma model [ 174 ]. Anti-CD30-LDM was radiolabeled with 123 I and demonstrated strong binding capabilities in CD30-positive cells, and a biodistribution study showed a 2-fold higher tumor uptake in CD30+ versus CD30- tumors (4.98 ± 0.99%ID/g vs. 2.75 ± 0.47%ID/g, respectively) [ 175 ]. These findings support the potential use of 123 I-anti-CD30-LDM as a companion diagnostic in the further clinical development of anti-CD30-LDM.

7.1.2. Tomoregulin (TENB2) and Six-Transmembrane Epithelial Antigen of the Prostate-1 (STEAP1)

The transmembrane proteins TENB2 and STEAP1 are commonly overexpressed in prostate cancer [ 176 , 177 ]. The therapeutic efficacy of ADCs targeting these antigens in a panel of patient-derived prostate cancer models was evaluated. In addition, parallel biodistribution and immunoPET studies were performed using corresponding 111 In and 89 Zr-radiolabeled mAbs to quantify tumor uptake and establish the relationship between imaging with therapeutic response [ 178 ]. In this study, both TENB2 and STEAP1 expression correlated with antibody uptake and ADC efficacy, indicating that this imaging approach may provide crucial information on the suitability of tumor type for ADC treatment.

7.1.3. Mesothelin (MSLN)

Mesothelin is a tumor antigen that is highly expressed in several tumor types and plays a vital role in promoting proliferation and invasion [ 179 ]. The efficacy of the mesothelin-targeting ADC, DMOT4039A, an anti-mesothelin antibody (AMA, MMOT0530A) conjugated to MMAE, was evaluated in a range of tumor models with different levels of MSLN expression [ 170 ]. Correlative molecular imaging to measure tumor antibody uptake by 89 Zr immunoPET imaging was also undertaken. ADC efficacy correlated with antigen expression and 89 Zr-MMOT0530A uptake six days post-injection was highest in tumors with high mesothelin expression. The less responsive xenografts did not show 89 Zr-AMA uptake despite confirmed mesothelin expression and this was attributed to lower MSLN expression levels and/or potential differences in target internalization. Encouraged by these preclinical findings, 89 Zr-AMA immunoPET has been translated to the clinic [ 180 ].

Another anti-MSLN antibody, MMOT05530A, was radiolabeled with 89 Zr for PET imaging of MSLN-expressing human pancreatic tumor xenografts. Biodistribution studies showed specific tumor uptake of 89 Zr-MMOT0530A at 10, 25, and 100 mg. PET data showed similar tumor uptake of 89 Zr-MMOT0530A that increased over six days, whereas activity in other tissues decreased. Ex vivo biodistribution analyses were consistent with imaging data for both xenograft models

7.1.4. Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5)

LGR5 is highly expressed in colorectal tumors and marks colon cancer stem cells that drive tumor growth and metastasis [ 181 ]. LGR5 overexpression was shown to correlate with poor clinical outcomes [ 182 ]. Two different anti-LGR5 monoclonal antibodies, 8F2 and 9G5, were evaluated using 89 Zr immunoPET to select the optimal mAb for ADC development and tumor imaging [ 181 ]. Two LGR5-targeting ADCs were generated by conjugating the anti-LGR5 mAb (anti-LGR5 mAb) to MMAE via a cleavable or non-cleavable chemical linker [ 183 ]. Both mAbs demonstrated high-affinity specific binding and rapidly internalized into lysosomes and promoted ADC-induced cytotoxicity in LGR5-overexpressing colon cell lines. 89 Zr-labeled mAbs retained high affinity and LGR5-dependent uptake in vitro. Biodistribution studies showed specific tumor uptake of 89 Zr-MMOT0530A at 10, 25, and 100 µg doses. PET data showed that tumor uptake of 89 Zr-MMOT0530A increased over six days while activity in other tissues decreased. Ex vivo biodistribution analyses conducted on tumoral cell lines were consistent with imaging data from the animal models. Based on the slightly higher potency, the investigators identified 8F2 as the optimal candidate for ADC development and this is also supported by the previous studies [ 183 ]. These studies provide a strong rationale for using 89 Zr immunoPET for the development of LGR5-targeted ADCs, target quantification and selecting patients likely to respond best to LGR5-targeted ADC therapy.

7.2. Clinical Studies

The role of molecular imaging in ADC clinical development has been demonstrated using SPECT and PET approaches. These clinical trials have utilized molecular imaging to evaluate the biodistribution and pharmacokinetics of ADCs and to measure target expression and deliverable ADC concentration to a tumor. This information is vital to understanding the in vivo behaviour of ADCs in patients in order to ensure the patient selection and ADC dose is optimized as well as to allow valid assessment of the therapeutic effects of ADCs.

CMD-193 is an ADC which is composed of G193, a humanized anti-Lewis Y (Le y ) monoclonal antibody based on Hu3S193, conjugated to cytotoxic calicheamicin via an acid-labile AcBut linker [ 184 ]. The Le y antigen (CD174) is a cell surface antigen expressed in various malignancies including breast, ovary, pancreas, colon, prostate, multiple myeloma and lung cancer. In preclinical studies, CMD-193 showed regression of Le y -expressing human carcinoma xenografts [ 185 ]. However, in a phase I dose escalation study of CMD-193 in patients with Le y -expressing advanced solid tumors, none of the nine patients showed a radiological response. This was the first clinical study which utilized a radiolabeled ADC ( 111 In-CMD-193) in order to evaluate the biodistribution and pharmacokinetics of an ADC [ 186 ]. Patients received a single infusion of 111 In-CMD-193, this was followed by unlabeled CMD-193 infusions every three weeks for the duration of the study. Biodistribution analysis was performed by whole-body gamma camera scans and SPECT over one week following 111 In-CMD-193 infusion. Biodistribution images revealed that there was a rapid clearance of 111 In-CMD-193 from blood followed by a marked increase in hepatic uptake, and no significant uptake in tumor ( Figure 4 ). This was in stark contrast to parental hu3S193 monoclonal antibody, which had a long half-life in blood, lower hepatic uptake and higher tumor uptake [ 187 ]. This physiochemical change in CMD-193 may have been induced by conjugation of mAb with cytotoxic payload calicheamicin [ 186 ]. Based on this study, the clinical development of CMD-193 was discontinued. This clinical trial highlighted the significance of molecular imaging to study the biodistribution and pharmacodynamics of drugs in the early phase of development.

Molecular imaging techniques are also under investigation to measure target expression in order to predict response to ADCs. The ZEPHIR trial was the first study to use the molecular imaging probe 89 Zr-trastuzumab to measure ErbB2 expression and predict response to T-DM1 [ 188 ]. In the ZEPHIR study, ErbB2-positive advanced metastatic breast cancer patients underwent ErbB2-PET ( 89 Zr-trastuzumab PET/CT) and FDG-PET/CT followed by FDG-PET/CT after once cycle of T-DM1 and standard CT scans after three cycles of therapy in order to assess response. The primary end point of the study was negative predictive value (NPV) for therapeutic response. Positive predictive value (PPV) and time to treatment failure (TTF) were also measured. The NPV and PPV for ErbB2-PET/CT were 88% and 72% respectively. The NPV and PPV for FDG-PET/CT were 83% and 96%, respectively. Combining ErbB2–PET/CT and FDG–PET/CT accurately predicted morphological response (NPV and PPV of 100%) and distinguished patients with a median TTF of only 2.8 months [n = 12, 95% confidence interval (CI) 1.4–7.6] from those with a TTF of 15 months (n = 25, 95% CI 9.7–not calculable) [ 188 ]. This study displayed the potential of molecular imaging as a companion diagnostic tool for ADC therapy in selecting patients who will/will not benefit from T-DM1. The same approach is being used to evaluate whether 64 Cu-labeled trastuzumab can predict response to T-DM1 therapy (ClinicalTrials.gov identifier NCT02226276 ).

Mesothelin (MSLN) is highly expressed in pancreatic and ovarian cancer [ 169 ]. Molecular imaging with 89 Zr-PET has been utilized in a phase I study to determine target antigen mesothelin expression, anti-mesothelin antibody tumor uptake, organ distribution at the whole body level, and the relationship between uptake and response to treatment in patients with advanced pancreatic and ovarian cancer. In this phase I study, 89 Zr-PET imaging with anti-MSLN antibody MMOT0530A was performed before patients received antibody–drug conjugate DMOT4039A, containing MMOT0530A bound to cytotoxic payload MMAE [ 154 ]. Patients received 37 MBq 89 Zr-MMOT0530A followed by PET/CT imaging 2, 4 and 7 days after injection. Maximum tumor uptake was detected four days post-injection. The SUV max was 11.5 ± 7.5 in pancreatic cancer patients and 15.5 ± 8.7 in ovarian cancer patients. 89 Zr-MMOT0530A uptake was observed in at least one tumor lesion in all patients (range 1–8). Six measurable lesions on diagnostic CT were not visible on PET scan. Within patients, a mean 2.4-fold difference in uptake between tumor lesions was observed. This difference was 5.3-fold between patients. Uptake in blood, liver, spleen and kidneys reflected normal antibody distribution. One patient out of eleven had a partial response, nine patients had stable disease and one patient had disease progression. Mean progression-free survival in this study was 121 days. Tracer tumor uptake was also correlated with immunohistochemistry of MSLN expression on archival tumor tissue. However, MSLN expression determined by IHC did not correlate with tracer uptake on PET scan in this study. This molecular imaging study with 89 Zr-PET allowed visualisation and quantification of ADC uptake in pancreatic and ovarian cancer lesions. It also allowed the chance to study biodistribution at the whole body level [ 180 ].

These clinical studies highlight the importance of utilizing molecular imaging for ADC drug development, allowing evaluation of whole-body and tumor target expression. In order to guide ADC dosing in large clinical trials, these studies also provide vital information about in vivo ADC stability and the potential healthy organs at risk of toxicity.

8. Conclusions and Future Perspectives

ADC development is encouraged by the success of ADCs for treatment of various haematological malignancies and solid organ tumors. The growing ADC market is projected to reach US$4 billion by 2023 [ 5 ]. The successful development of ADCs requires a sophisticated understanding of target expression, ADC in vivo properties, drug delivery parameters and the pharmacodynamic profile of therapeutic activity in preclinical studies and in subsequent clinical trials. Combination therapies have the capability of reducing drug resistance and improving drug efficacy. Various clinical trials are now testing ADCs with other drugs including conventional chemotherapeutic regimens, tyrosine kinase inhibitors and checkpoint inhibitors in order to prevent the development of refractory disease. In future, ADC-based regimens would be incorporated earlier in the patient’s treatment course along with combination therapies to maximize therapeutic effects.

Molecular imaging has been successfully used in ADC development to study the biodistribution and pharmacodynamics of ADCs to determine target expression in the tumor and to detect interlesional heterogeneity in order to predict response to ADCs. As we use advanced molecular imaging methods to aid clinical decision making, we should consider several important issues. Firstly, the use of molecular imaging to guide clinical decision making requires prospective validation to demonstrate that initiating or ceasing treatment based on molecular imaging results in improved patient outcomes. Optimization of molecular imaging approaches and standardization of protocols will also assist in providing more accurate and reproducible data that can assist with decision making in drug development. In addition, advances in radiochemistry and conjugation approaches will result in improved immunoconjugate properties and facilitate the quantitative assessment of ADC target expression and drug delivery to the tumor in patients.

In conclusion, ADCs are drugs with enormous potential for the treatment of haematological malignancies and solid tumors, and strategies to manage toxicities and improve efficacy warrant further exploration. Advances in molecular imaging can make major contributions to ADC development in both preclinical studies and clinical trials, informing patient selection and optimizing outcomes.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

Conceptualization, U.H. and A.M.S.; Writing—Review & and Editing, U.H., S.P., H.K.G. and A.M.S.; Supervision, A.M.S.; Funding Acquisition, A.M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This review was supported in part by grants from NHMRC (No. 1092788), the Cancer Council of Victoria (No. 1164229) and the Operational Infrastructure Support Program provided by the Victorian Government and is acknowledged. Andrew Scott is supported by an NHMRC Investigator Fellowship (No. 1177837).

Conflicts of Interest

Andrew Scott has consulting roles and research funding from EMD Serono, Abbvie, Astra Zeneca, Telix, Medimmune, Adalta, ITM, and Imagion Bio; he is a consultant to Life Science Pharmaceuticals.

References

1. Factsheet W. Cancer Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 29 November 2019)

2. Davis C. Naci H. Gurpinar E. Poplavska E. Pinto A. Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009–13 BMJ 2017 359 j4530 10.1136/bmj.j4530 28978555 PMC5627352

3. Weiner G.J. Building better monoclonal antibody-based therapeutics Nat. Rev. Cancer 2015 15 361 370 10.1038/nrc3930 25998715 PMC4491443

4. Sievers E.L. Senter P.D. Antibody-Drug Conjugates in Cancer Therapy Annu. Rev. Med. 2013 64 15 29 10.1146/annurev-med-050311-201823 23043493

5. Sharma V. CPhI Annual Report 2018: ADCs Growth Driven by Lack of In-House Facilities, Oncology and Integrated CDMOs Available online: https://www.pharmoutsourcing.com/Featured-Articles/354437-CPhI-Annual-Report-2018-ADCs-Growth-Driven-by-Lack-of-In-House-Facilities-Oncology-and-Integrated-CDMOs/ (accessed on 7 July 2020)

6. Chau C.H. Steeg P.S. Figg W.D. Antibody–drug conjugates for cancer Lancet 2019 394 793 804 10.1016/S0140-6736(19)31774-X 31478503

7. Redman J.M. Hill E.M. AlDeghaither D. Weiner L.M. Mechanisms of action of therapeutic antibodies for cancer Mol. Immunol. 2015 67 28 45 10.1016/j.molimm.2015.04.002 25911943 PMC4529810

8. Hafeez U. Gan H.K. Scott A.M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases Curr. Opin. Pharm. 2018 41 114 121 10.1016/j.coph.2018.05.010 29883853

9. Smith L.M. Nesterova A. Alley S.C. Torgov M.Y. Carter P.J. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97 Mol. Cancer Ther. 2006 5 1474 10.1158/1535-7163.MCT-06-0026 16818506

10. Perez H.L. Cardarelli P. Deshpande S. Gangwar S. Schroeder G. Vite G. Borzilleri R.M. Antibody-drug conjugates: Current status and future directions Drug Discov. Today 2014 19 869 881 10.1016/j.drudis.2013.11.004 24239727

11. Gutierrez C. Schiff R. HER2: Biology, detection, and clinical implications Arch. Pathol. Lab. Med. 2011 135 55 62 10.1043/2010-0454-RAR.1 21204711 PMC3242418

12. Ingle G.S. Chan P. Elliott J.M. Chang W.S. Koeppen H. Stephan J.P. Scales S.J. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate Br. J. Haematol. 2008 140 46 58 10.1111/j.1365-2141.2007.06883.x 17991300 PMC2228374

13. Ritchie M. Tchistiakova L. Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates mAbs 2013 5 13 21 10.4161/mabs.22854 23221464 PMC3564878

14. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates mAbs 2016 8 659 671 10.1080/19420862.2016.1156829 27045800 PMC4966843

15. Sapra P. Stein R. Pickett J. Qu Z. Govindan S.V. Cardillo T.M. Hansen H.J. Horak I.D. Griffiths G.L. Goldenberg D.M. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2005 11 5257 10.1158/1078-0432.CCR-05-0204 16033844

16. Teicher B.A. Chari R.V. Antibody conjugate therapeutics: Challenges and potential Clin. Cancer Res. 2011 17 6389 6397 10.1158/1078-0432.CCR-11-1417 22003066

17. Hughes B. Antibody-drug conjugates for cancer: Poised to deliver? Nat. Rev. Drug Discov. 2010 9 665 667 10.1038/nrd3270 20811367

18. Khongorzul P. Ling C.J. Khan F.U. Ihsan A.U. Zhang J. Antibody-Drug Conjugates: A Comprehensive Review Mol. Cancer Res. 2020 18 3 19 10.1158/1541-7786.MCR-19-0582 31659006

19. Derry C.R. Shreeram A. FcRn: The neonatal Fc receptor comes of age Nat. Rev. Immunol. 2007 7 715 10.1038/nri2155 17703228

20. Vidarsson G. Dekkers G. Rispens T. IgG subclasses and allotypes: From structure to effector functions Front. Immunol. 2014 5 520 10.3389/fimmu.2014.00520 25368619 PMC4202688

21. Jochen G.S. Isotype selection in antibody engineering Nat. Biotechnol. 2007 25 1369 10.1038/nbt1207-1369 18066027

22. Correia I.R. Stability of IgG isotypes in serum mAbs 2010 2 221 232 10.4161/mabs.2.3.11788 20404539 PMC2881250

23. Adlersberg J.B. The immunoglobulin hinge (Interdomain) region Ric. Clin. E Lab. 1976 6 191 10.1007/BF02899970 828971

24. Saito S. Namisaki H. Hiraishi K. Takahashi N. Iida S. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress Protein Sci. 2019 28 900 909 10.1002/pro.3598 30834577 PMC6459999

25. Hoffmann R.M. Coumbe B.G.T. Josephs D.H. Mele S. Ilieva K.M. Cheung A. Tutt A.N. Spicer J.F. Thurston D.E. Crescioli S. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs) Oncoimmunology 2017 7 e1395127 10.1080/2162402X.2017.1395127 29375935 PMC5769674

26. L’Italien L. Orozco O. Abrams T. Cantagallo L. Connor A. Desai J. Ebersbach H. Gelderblom H. Hoffmaster K. Lees E. Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies Clin. Cancer Res. 2018 24 3465 3474 10.1158/1078-0432.CCR-17-3786 29615457

27. Wang Y.-J. Li Y.-Y. Liu X.-Y. Lu X.-L. Cao X. Jiao B.-H. Marine Antibody-Drug Conjugates: Design Strategies and Research Progress Mar. Drugs 2017 15 18 10.3390/md15010018 PMC5295238 28098746

28. Yasunaga M. Manabe S. Tsuji A. Furuta M. Ogata K. Koga Y. Saga T. Matsumura Y. Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging Bioengineering 2017 4 78 10.3390/bioengineering4030078 28952557 PMC5615324

29. Verma S. Miles D. Gianni L. Krop I.E. Welslau M. Basal J. Pegram M. Do-Youn O. Dieras V. Guardino E. Trastuzumab Emtansine for HER2-positive advanced breast cancer. (Clinical report) N. Engl. J. Med. 2012 367 1783 10.1056/NEJMoa1209124 23020162 PMC5125250

30. Shen W.C. Ballou B. Ryser H.J. Hakala T.R. Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells Cancer Res. 1986 46 3912 3916 2873883

31. Johnson D.A. Laguzza B.C. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D Cancer Res. 1987 47 3118 3122 10.1016/0378-8741(88)90249-8 3495327

32. Dillman R.O. Johnson D.E. Shawler D.L. Koziol J.A. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug Cancer Res. 1988 48 6097 6102 3262420

33. Tolcher A.W. Sugarman S. Gelmon K.A. Cohen R. Saleh M. Isaacs C. Young L. Healey D. Onetto N. Slichenmyer W. Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients with Metastatic Breast Cancer J. Clin. Oncol. 1999 17 478 10.1200/JCO.1999.17.2.478 10080588

34. Senter P.D. Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 2009 13 235 244 10.1016/j.cbpa.2009.03.023 19414278

35. Wellcome Sanger Institute Genomics of Drug Sensitivity in Cancer Available online: https://www.cancerrxgene.org/compound/Mitomycin-C/136/overview/ic50 (accessed on 13 July 2020)

36. Li F. Emmerton K.K. Jonas M. Zhang X. Miyamoto J.B. Setter J.R. Nicholas N.D. Okeley N.M. Lyon R.P. Benjamin D.R. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models Cancer Res. 2016 76 2710 2719 10.1158/0008-5472.CAN-15-1795 26921341

37. Kantarjian H.M. DeAngelo D.J. Stelljes M. Martinelli G. Liedtke M. Stock W. Gökbuget N. O’Brien S. Wang K. Wang T. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia N. Engl. J. Med. 2016 375 740 753 10.1056/NEJMoa1509277 27292104 PMC5594743

38. Elgersma R.C. Coumans R.G.E. Huijbregts T. Menge W.M.P.B. Joosten J.A.F. Spijker H.J. de Groot F.M.H. van der Lee M.M.C. Ubink R. van den Dobbelsteen D.J. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985 Mol. Pharm. 2015 12 1813 1835 10.1021/mp500781a 25635711

39. Banerji U. van Herpen C.M.L. Saura C. Thistlethwaite F. Lord S. Moreno V. Macpherson I.R. Boni V. Rolfo C. de Vries E.G.E. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study Lancet Oncol. 2019 20 1124 1135 10.1016/S1470-2045(19)30328-6 31257177

40. Mantaj J. Jackson P.J.M. Karu K. Rahman K.M. Thurston D.E. Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments PLoS ONE 2016 11 e0152303 10.1371/journal.pone.0152303 27055050 PMC4824457

41. Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines Med. Res. Rev. 2012 32 254 293 10.1002/med.20212 20544978 PMC4127195

42. Kahl B.S. Hamadani M. Radford J. Carlo-Stella C. Caimi P. Reid E. Feingold J.M. Ardeshna K.M. Solh M. Heffner L.T. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma Clin. Cancer Res. 2019 25 6986 6994 10.1158/1078-0432.CCR-19-0711 31685491

43. Starodub A.N. Ocean A.J. Shah M.A. Guarino M.J. Picozzi V.J. Jr. Vahdat L.T. Thomas S.S. Govindan S.V. Maliakal P.P. Wegener W.A. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Clin. Cancer Res. 2015 21 3870 3878 10.1158/1078-0432.CCR-14-3321 25944802 PMC4558321

44. Ogitani Y. Aida T. Hagihara K. Yamaguchi J. Ishii C. Harada N. Soma M. Okamoto H. Oitate M. Arakawa S. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 Clin. Cancer Res. 2016 22 5097 5108 10.1158/1078-0432.CCR-15-2822 27026201

45. Modi S. Saura C. Yamashita T. Park Y.H. Kim S.B. Tamura K. Andre F. Iwata H. Ito Y. Tsurutani J. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer N. Engl. J. Med. 2020 382 610 621 10.1056/NEJMoa1914510 31825192 PMC7458671

46. Trendowski M. Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Drugs 2015 75 1993 2016 10.1007/s40265-015-0489-4 26501980 PMC4642600

47. Chen H. Lin Z. Arnst K.E. Miller D.D. Li W. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy Molecules 2017 22 1281 10.3390/molecules22081281 PMC6152078 28763044

48. Sehn L.H. Herrera A.F. Flowers C.R. Kamdar M.K. McMillan A. Hertzberg M. Assouline S. Kim T.M. Kim W.S. Ozcan M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma J. Clin. Oncol. 2020 38 155 165 10.1200/JCO.19.00172 31693429 PMC7032881

49. Challita-Eid P.M. Satpayev D. Yang P. An Z. Morrison K. Shostak Y. Raitano A. Nadell R. Liu W. Lortie D.R. Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models Cancer Res. 2016 76 3003 3013 10.1158/0008-5472.CAN-15-1313 27013195

50. AbbVie News Center AbbVie Provides Update on Depatuxizumab Mafodotin Depatux-M, An Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer AbbVie News Center Chicago, IL, USA 2019 Volume 3

51. Kupchan S.M. Komoda Y. Court W.A. Thomas G.J. Smith R.M. Karim A. Gilmore C.J. Haltiwanger R.C. Bryan R.F. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus J. Am. Chem. Soc. 1972 94 1354 1356 10.1021/ja00759a054 5062169

52. Lopus M. Oroudjev E. Wilson L. Wilhelm S. Widdison W. Chari R. Jordan M.A. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules Mol. Cancer Ther. 2010 9 2689 2699 10.1158/1535-7163.MCT-10-0644 20937594 PMC2954514

53. Ott P.A. Hamid O. Pavlick A.C. Kluger H. Kim K.B. Boasberg P.D. Simantov R. Crowley E. Green J.A. Hawthorne T. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma J. Clin. Oncol. 2014 32 3659 3666 10.1200/JCO.2013.54.8115 25267741 PMC4879709

54. Amiri-Kordestani L. Blumenthal G.M. Xu Q.C. Zhang L. Tang S.W. Ha L. Weinberg W.C. Chi B. Candau-Chacon R. Hughes P. FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer Clin. Cancer Res. 2014 20 4436 4441 10.1158/1078-0432.CCR-14-0012 24879797

55. Senter P.D. Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 2012 30 631 637 10.1038/nbt.2289 22781692

56. Dowell J.A. Korth-Bradley J. Liu H. King S.P. Berger M.S. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse J. Clin. Pharm. 2001 41 1206 1214 10.1177/00912700122012751 11697753

57. Hamann P.R. Hinman L.M. Hollander I. Beyer C.F. Lindh D. Holcomb R. Hallett W. Tsou H.R. Upeslacis J. Shochat D. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug. Chem. 2002 13 47 58 10.1021/bc010021y 11792178

58. Wynne J. Wright D. Stock W. Inotuzumab: From preclinical development to success in B-cell acute lymphoblastic leukemia Blood Adv. 2019 3 96 10.1182/bloodadvances.2018026211 30622147 PMC6325303

59. Gymnopoulos M. Betancourt O. Blot V. Fujita R. Galvan D. Lieuw V. Nguyen S. Snedden J. Stewart C. Villicana J. TR1801-ADC: A highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors Mol. Oncol. 2020 14 54 68 10.1002/1878-0261.12600 31736230 PMC6944112

60. Balendiran G.K. Dabur R. Fraser D. The role of glutathione in cancer Cell Biochem. Funct. 2004 22 343 352 10.1002/cbf.1149 15386533

61. Moore K.N. Martin L.P. O’Malley D.M. Matulonis U.A. Konner J.A. Vergote I. Ponte J.F. Birrer M.J. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer Future Oncol. 2018 14 123 136 10.2217/fon-2017-0379 29098867

62. Erickson H.K. Park P.U. Widdison W.C. Kovtun Y.V. Garrett L.M. Hoffman K. Lutz R.J. Goldmacher V.S. Blättler W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 2006 66 4426 4433 10.1158/0008-5472.CAN-05-4489 16618769

63. Barok M. Joensuu H. Isola J. Trastuzumab emtansine: Mechanisms of action and drug resistance Breast Cancer Res. 2014 16 209 10.1186/bcr3621 24887180 PMC4058749

64. Lee L. Bounds D. Paterson J. Herledan G. Sully K. Seestaller-Wehr L.M. Fieles W.E. Tunstead J. McCahon L. Germaschewski F.M. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma Br. J. Haematol. 2016 174 911 922 10.1111/bjh.14145 27313079

65. Shefet-Carasso L. Benhar I. Antibody-targeted drugs and drug resistance—Challenges and solutions Drug Resist. Updates 2015 18 36 46 10.1016/j.drup.2014.11.001 25476546

66. Junutula J.R. Raab H. Clark S. Bhakta S. Leipold D.D. Weir S. Chen Y. Simpson M. Tsai S.P. Mark S.D. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008 26 925 10.1038/nbt.1480 18641636

67. Hamblett K.J. Senter P.D. Chace D.F. Sun M.M.C. Lenox J. Cerveny C.G. Kissler K.M. Bernhardt S.X. Kopcha A.K. Zabinski R.F. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004 10 7063 10.1158/1078-0432.CCR-04-0789 15501986

68. Hallam T.J. Wold E. Wahl A. Smider V.V. Antibody Conjugates with Unnatural Amino Acids Mol. Pharm. 2015 12 1848 1862 10.1021/acs.molpharmaceut.5b00082 25898256

69. Junutula J.R. Bhakta S. Raab H. Ervin K.E. Eigenbrot C. Vandlen R. Scheller R.H. Lowman H.B. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 2008 332 41 52 10.1016/j.jim.2007.12.011 18230399

70. David R. Jason S.R. Gregory W.D. Peng W. Carolyn R.B. Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 2012 7 1052 10.1038/nprot.2012.045 22576105 PMC3498491

71. Sunbul M. Yin J. Site specific protein labeling by enzymatic posttranslational modification Org. Biomol. Chem. 2009 7 3361 3371 10.1039/b908687k 19675886

72. Gauzy-Lazo L. Sassoon I. Brun M.-P. Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations SLAS Discov. Adv. Sci. Drug Discov. 2020 25 843 868 10.1177/2472555220912955 32192384

73. Sean D.C. Sandra L.S. Regulated portals of entry into the cell Nature 2003 422 37 10.1038/nature01451 12621426

74. Kalim M. Chen J. Wang S. Lin C. Ullah S. Liang K. Ding Q. Chen S. Zhan J. Intracellular trafficking of new anticancer therapeutics: Antibody-drug conjugates Drug Des. Dev. Ther. 2017 11 2265 2276 10.2147/DDDT.S135571 PMC5546728 28814834

75. Chalouni C. Doll S. Fate of Antibody-Drug Conjugates in Cancer Cells J. Exp. Clin. Cancer Res. 2018 37 20 10.1186/s13046-017-0667-1 29409507 PMC5802061

76. Alexander H.S. Michael P.B. Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required? Br. J. Cancer 2017 117 1736 10.1038/bjc.2017.367 29065110 PMC5729478

77. Khera E. Thurber G. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates BioDrugs 2018 32 465 480 10.1007/s40259-018-0302-5 30132210

78. Fuh F.K. Looney C. Li D. Poon K.A. Dere R.C. Danilenko D.M. McBride J. Reed C. Chung S. Zheng B. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells Br. J. Pharm. 2017 174 628 640 10.1111/bph.13697 28009435 PMC5368047

79. Deckert J. Park P.U. Chicklas S. Yi Y. Li M. Lai K.C. Mayo M.F. Carrigan C.N. Erickson H.K. Pinkas J. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies Blood 2013 122 3500 3510 10.1182/blood-2013-05-505685 24002446

80. Pro B. Advani R. Brice P. Bartlett N.L. Rosenblatt J.D. Illidge T. Matous J. Ramchandren R. Fanale M. Connors J.M. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study J. Clin. Oncol. 2012 30 2190 2196 10.1200/JCO.2011.38.0402 22614995

81. Chen R. Wang F. Zhang H. Chen B. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: Results of a systematic review and meta-analysis of prospective studies Drug Des. Devel. Ther. 2015 9 2277 2283 10.2147/dddt.S83592 PMC4408955 25945039

82. LaCasce A.S. Bociek R.G. Sawas A. Caimi P. Agura E. Matous J. Ansell S.M. Crosswell H.E. Islas-Ohlmayer M. Behler C. Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma Blood 2018 132 40 48 10.1182/blood-2017-11-815183 29703778 PMC6073588

83. Horwitz S.M. Advani R.H. Bartlett N.L. Jacobsen E.D. Sharman J.P. O’Connor O.A. Siddiqi T. Kennedy D.A. Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Blood 2014 123 3095 3100 10.1182/blood-2013-12-542142 24652992 PMC4425442

84. Prince H.M. Kim Y.H. Horwitz S.M. Dummer R. Scarisbrick J. Quaglino P. Zinzani P.L. Wolter P. Sanches J.A. Ortiz-Romero P.L. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial Lancet 2017 390 555 566 10.1016/S0140-6736(17)31266-7 28600132

85. Connors J.M. Jurczak W. Straus D.J. Ansell S.M. Kim W.S. Gallamini A. Younes A. Alekseev S. Illés Á. Picardi M. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma N. Engl. J. Med. 2018 378 331 344 10.1056/NEJMoa1708984 29224502 PMC5819601

86. Horwitz S. O’Connor O.A. Pro B. Illidge T. Fanale M. Advani R. Bartlett N.L. Christensen J.H. Morschhauser F. Domingo-Domenech E. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial Lancet 2019 393 229 240 10.1016/S0140-6736(18)32984-2 30522922 PMC6436818

87. Wagner-Johnston N.D. Bartlett N.L. Cashen A. Berger J.R. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin Leuk. Lymphoma 2012 53 2283 2286 10.3109/10428194.2012.676170 22424602

88. Urru S.A. Mariotti E. Carta P. Massidda S. Marcias M. Murru R. Sanna P. Angelucci E. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: A case report Drugs R&D 2014 14 9 11 10.1007/s40268-014-0036-x PMC3964296 24493291

89. Krop I.E. Beeram M. Modi S. Jones S.F. Holden S.N. Yu W. Girish S. Tibbitts J. Yi J.H. Sliwkowski M.X. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J. Clin. Oncol. 2010 28 2698 2704 10.1200/JCO.2009.26.2071 20421541

90. Krop I.E. Kim S.-B. Martin A.G. Lorusso P.M. Ferrero J.-M. Badovinac-Crnjevic T. Hoersch S. Smitt M. Wildiers H. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial Lancet Oncol. 2017 18 743 754 10.1016/S1470-2045(17)30313-3 28526538

91. Kantarjian H.M. DeAngelo D.J. Advani A.S. Stelljes M. Kebriaei P. Cassaday R.D. Merchant A.A. Fujishima N. Uchida T. Calbacho M. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study Lancet Haematol. 2017 4 e387 e398 10.1016/S2352-3026(17)30103-5 28687420

92. Bross P.F. Beitz J. Chen G. Chen X.H. Duffy E. Kieffer L. Roy S. Sridhara R. Rahman A. Williams G. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2001 7 1490 11410481

93. Petersdorf S.H. Kopecky K.J. Slovak M. Willman C. Nevill T. Brandwein J. Larson R.A. Erba H.P. Stiff P.J. Stuart R.K. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Blood 2013 121 4854 4860 10.1182/blood-2013-01-466706 23591789 PMC3682338

94. Castaigne S. Pautas C. Terré C. Raffoux E. Bordessoule D. Bastie J.-N. Legrand O. Thomas X. Turlure P. Reman O. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study Lancet 2012 379 1508 1516 10.1016/S0140-6736(12)60485-1 22482940

95. Amadori S. Suciu S. Selleslag D. Aversa F. Gaidano G. Musso M. Annino L. Venditti A. Voso M.T. Mazzone C. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016 34 972 10.1200/JCO.2015.64.0060 26811524

96. Rosenberg J.E. O’Donnell P.H. Balar A.V. McGregor B.A. Heath E.I. Yu E.Y. Galsky M.D. Hahn N.M. Gartner E.M. Pinelli J.M. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019 37 2592 10.1200/JCO.19.01140 31356140 PMC6784850

97. Bardia A. Mayer I.A. Vahdat L.T. Tolaney S.M. Isakoff S.J. Diamond J.R. O’Shaughnessy J. Moroose R.L. Santin A.D. Abramson V.G. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer N. Engl. J. Med. 2019 380 741 751 10.1056/NEJMoa1814213 30786188

98. Trudel S. Lendvai N. Popat R. Voorhees P.M. Reeves B. Libby E.N. Richardson P.G. Hoos A. Gupta I. Bragulat V. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study Blood Cancer J. 2019 9 37 10.1038/s41408-019-0196-6 30894515 PMC6426965

99. Sanchez E. Li M. Kitto A. Li J. Wang C.S. Kirk D.T. Yellin O. Nichols C.M. Dreyer M.P. Ahles C.P. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival Br. J. Haematol. 2012 158 727 738 10.1111/j.1365-2141.2012.09241.x 22804669

100. Lonial S. Lee H.C. Badros A. Trudel S. Nooka A.K. Chari A. Abdallah A.-O. Callander N. Lendvai N. Sborov D. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study Lancet Oncol. 2020 21 207 221 10.1016/S1470-2045(19)30788-0 31859245

101. Snyder J.T. Malinao M.-C. Dugal-Tessier J. Atkinson J.E. Anand B.S. Okada A. Mendelsohn B.A. Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of its Identified Metabolite Mol. Pharm. 2018 15 2384 2390 10.1021/acs.molpharmaceut.8b00225 29757653

102. Meric-Bernstam F. Calvo E. Moreno V. Chung H.C. Park Y.H. Bang Y.-J. Rosen L.S. Mita M.M. Garrido-Laguna I. Leung A.C.F. A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors J. Clin. Oncol. 2020 38 1039 10.1200/JCO.2020.38.15_suppl.1039

103. Sachdev J.C. Maitland M.L. Sharma M. Moreno V. Boni V. Kummar S. Stringer-Reasor E.M. Forero-Torres A. Lakhani N.J. Gibson B. PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study J. Clin. Oncol. 2018 36 5565 10.1200/JCO.2018.36.15_suppl.5565

104. Akla B. Broussas M. Loukili N. Robert A. Beau-Larvor C. Malissard M. Boute N. Champion T. Haeuw J.-F. Beck A. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors Mol. Cancer Ther. 2020 19 168 177 10.1158/1535-7163.MCT-19-0219 31594825

105. Hamblett K. Barnscher S.D. Davies R.H. Hammond P. Hernandez A. Wickman G. Fung V. Ding T. Garnett G. Galey A. Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers Cancer Res. 2019 79 Suppl. 4 P6-7-13 P16-17-13 10.1158/1538-7445.SABCS18-P6-17-13

106. Hamilton E.B.M. Tolcher A. Buscema J. Papadopoulos K.P. Zarwan C. Anderson C. Doroshow D. Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study News Bites Pty Ltd. Melbourne, Australia 2020

107. Gourd K. San Antonio Breast Cancer Symposium 2019 Lancet Oncol. 2020 21 28 10.1016/S1470-2045(19)30830-7 31866168

108. Tang W. Huang X. Ou Z. Yan H. Gan J. Dong Q. Tan B. Yang Y. Guo Y. Li S. Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer Cancer Res. 2019 79 Suppl. 4 P6-20-16 P26-20-16 10.1158/1538-7445.SABCS18-P6-20-16

109. Ko A.H. Coveler A.L. Schlechter B.L. Bekaii-Saab T.S. Wolpin B.M. Clark J.W. Cheng Y.-L. Cheng T.-Y. Langecker P.J. Lin S.-Y. Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers J. Clin. Oncol. 2020 38 713 10.1200/JCO.2020.38.4_suppl.713

110. Shen Y. Yang T. Cao X. Zhang Y. Zhao L. Li H. Zhao T. Xu J. Zhang H. Guo Q. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity mAbs 2019 11 1149 1161 10.1080/19420862.2019.1618674 31161871 PMC6748589

111. Stathis A. Flinn I.W. Madan S. Maddocks K. Freedman A. Weitman S. Zucca E. Munteanu M.C. Palomba M.L. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study Investig. New Drugs 2018 36 869 876 10.1007/s10637-018-0570-4 29453628 PMC6153548

112. Berdeja J.G. Ailawadhi S. Weitman S.D. Zildjian S. O’Leary J.J. O’Keeffe J. Guild R. Whiteman K. Chanan-Khan A.A.A. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM) J. Clin. Oncol. 2011 29 8013 10.1200/jco.2011.29.15_suppl.8013

113. Socinski M.A. Kaye F.J. Spigel D.R. Kudrik F.J. Ponce S. Ellis P.M. Majem M. Lorigan P. Gandhi L. Gutierrez M.E. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease Clin. Lung. Cancer 2017 18 68 76.e62 10.1016/j.cllc.2016.09.002 28341109

114. Whiteman K.R. Johnson H.A. Mayo M.F. Audette C.A. Carrigan C.N. LaBelle A. Zukerberg L. Lambert J.M. Lutz R.J. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models mAbs 2014 6 556 566 10.4161/mabs.27756 24492307 PMC3984343

115. Tolcher A. Papadopoulos K. Cole Y. Rivas K. Chandana S. Sinclair S. Wood D. Nadler P.I. Lakhani N. A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate Ann. Oncol. 2018 29 iii8 10.1093/annonc/mdy048.004

116. Merlino G. Fiascarelli A. Bigioni M. Bressan A. Carrisi C. Bellarosa D. Salerno M. Bugianesi R. Manno R. Bernadó Morales C. MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors Mol. Cancer Ther. 2019 18 1533 1543 10.1158/1535-7163.MCT-18-0624 31227646

117. Jagannath S. Heffner L.T. Jr. Ailawadhi S. Munshi N.C. Zimmerman T.M. Rosenblatt J. Lonial S. Chanan-Khan A. Ruehle M. Rharbaoui F. Indatuximab Ravtansine (BT062) Monotherapy in Patients with Relapsed and/or Refractory Multiple Myeloma Clin. Lymphoma Myeloma Leuk. 2019 19 372 380 10.1016/j.clml.2019.02.006 30930134

118. Ikeda H. Hideshima T. Fulciniti M. Lutz R.J. Yasui H. Okawa Y. Kiziltepe T. Vallet S. Pozzi S. Santo L. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res. 2009 15 4028 4037 10.1158/1078-0432.CCR-08-2867 19509164

119. Garcia-Corbacho J. Spira A. Boni V. Feliu J. Middleton M. Burris H. Yang Weaver A. Will M. Harding J. Meric-Bernstam F. PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors Ann. Oncol. 2017 28 v140 10.1093/annonc/mdx367.055

120. Gazzah A. Cousin S. Boni V. Ricordel C. Kim T.M. Kim J.-S. Helissey C. Gardeazabal I. Chadjaa M. Allard A. First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) J. Clin. Oncol. 2019 37 9072 10.1200/JCO.2019.37.15_suppl.9072

121. Moore K.N. Matulonis U.A. O’Malley D.M. Konner J.A. Martin L.P. Perez R.P. Bauer T.M. Gilbert L. Seward S.M. Oza A.M. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts J. Clin. Oncol. 2017 35 5547 10.1200/JCO.2017.35.15_suppl.5547 PMC5559878 28029313

122. Bendell J. Blumenschein G. Zinner R. Hong D. Jones S. Infante J. Burris H. Rajagopalan P. Kornacker M. Henderson D. Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors Cancer Res. 2013 73 Suppl. 8 LB-291 10.1158/1538-7445.Am2013-lb-291

123. Hassan R. Jr G.R.B. Moore K.N. Santin A.D. Kindler H.L. Nemunaitis J.J. Seward S.M. Thomas A. Kim S.K. Rajagopalan P. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors J. Clin. Oncol. 2020 38 1824 1835 10.1200/JCO.19.02085 32213105 PMC7255978

124. Scribner J.A. Brown J.G. Sharma S. Li H. Chiechi M. Li P. Son T. Costa A.D. Chen Y. Chen F. Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer Cancer Res. 2018 78 820 10.1158/1538-7445.Am2018-820 32967924

125. Masuda N. Yonemori K. Takahashi S. Kogawa T. Nakayama T. Iwase H. Takahashi M. Toyama T. Saeki T. Saji S. Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial Cancer Res. 2019 79 Suppl. 4 PD1-03 10.1158/1538-7445.sabcs18-pd1-03

126. Iida K. Abdelhamid A.H. Nagatsuma A.K. Shibutani T. Yasuda S. Kitamura M. Hattori C. Abe M. Hasegawa J. Iguchi T. Abstract 5181: Therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumor (GIST), with DS-6157a, an antibody-drug conjugate (ADC) Cancer Res. 2020 80 5181 10.1158/1538-7445.Am2020-5181 33579785

127. Sands J.M. Shimizu T. Garon E.B. Greenberg J. Guevara F.M. Heist R.S. Kobayashi F. Noguchi Y. Okajima D. Tajima N. First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors J. Clin. Oncol. 2019 37 9051 10.1200/JCO.2019.37.15_suppl.9051

128. Cheng X. Li J. Tanaka K. Majumder U. Milinichik A.Z. Verdi A.C. Maddage C.J. Rybinski K.A. Fernando S. Fernando D. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity Mol. Cancer Ther. 2018 17 2665 2675 10.1158/1535-7163.MCT-17-1215 30262588

129. Daver N.G. Erba H.P. Papadantonakis N. DeAngelo D.J. Wang E.S. Konopleva M.Y. Sloss C.M. Culm-Merdek K. Zweidler-McKay P.A. Kantarjian H.M. A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies Blood 2018 132 27 10.1182/blood-2018-99-112955

130. Koopman L.A. Janmaat M.L. Jacobsen K. Terp M.G. Heuvel E.G.-V.D. Forssman U. Lingnau A. Parren P.W. Ditzel H. Breij E.C. Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC Cancer Res. 2018 78 832 10.1158/1538-7445.AM2018-832

131. Ahnert J.R. Taylor M.H. O’Reilly E.M. Zhang J. Doebele R.C. Ben Y. Sharp L.L. Boyle W.J. Chang C. Frey G. A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors J. Clin. Oncol. 2018 36 TPS12126 10.1200/JCO.2018.36.15_suppl.TPS12126

132. Johnson M.L. El-Khoueiry A.B. Hafez N. Lakhani N.J. Mamdani H. Ahnert J.R. Sanborn R.E. Ho T. Li R. Waldes J. CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer J. Clin. Oncol. 2020 38 3502 10.1200/JCO.2020.38.15_suppl.3502

133. Patnaik A. Meric-Bernstam F. Lima C.M.S.P.R. Robert F. Dowlati A. Kindler H.L. Davar D. Powell S.F. Garfin P.M. Balmanoukian A.S. SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors J. Clin. Oncol. 2020 38 TPS3652 10.1200/JCO.2020.38.15_suppl.TPS3652

134. Goldman J. Angevin E. Strickler J. Camidge D. Heist R. Morgensztern D. Barve M. Yue H. Beaulieu J. Motwani M. Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC J. Thorac. Oncol. 2017 12 S1805 S1806 10.1016/j.jtho.2017.09.458

135. Xu B. Wang J. Fang J. Chen X. Han Y. Li Q. Zhang P. Yuan P. Ma F. Luo Y. Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer Cancer Res. 2020 80 PD4-06 10.1158/1538-7445.Sabcs19-pd4-06

136. Jiang J. Li S. Shan X. Wang L. Ma J. Huang M. Dong L. Chen F. Preclinical safety profile of disitamab vedotin: A novel anti-HER2 antibody conjugated with MMAE Toxicol. Lett. 2020 324 30 37 10.1016/j.toxlet.2019.12.027 31877330

137. Alteogen Secures FDA Approval for Orphan Drug Designation with An Antibody-Drug Conjugate for Gastric Cancer Health & Beauty Close-Up Alteogen Inc. Daejeon, Korea 2018

138. Li J. Guo Y. Xue J. Peng W. Ge X. Zhao W. Dai C. Xue L. Tang W. Hu C. First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors J. Clin. Oncol. 2020 38 TPS1101 10.1200/JCO.2020.38.15_suppl.TPS1101

139. OBI Pharma, Inc. Press Release: OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer OBI Pharma, Inc. New York, NY, USA 2018

140. Vaisitti T. Jessen K. Vo T.-T. Ko M. Arruga F. Vitale N. Braggio E. Di Napoli A. Chadburn A. Allan J.N. Vls-101 is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter’s Syndrome (RS) Blood 2019 134 2856 10.1182/blood-2019-126827

141. Han H. Diab S. Alemany C. Basho R. Brown-Glaberman U. Meisel J. Pluard T. Cortes J. Dillon P. Ettl J. Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer Cancer Res. 2020 80 PD1-06-PD01-06 10.1158/1538-7445.Sabcs19-pd1-06

142. De Bono J.S. Concin N. Hong D.S. Thistlethwaite F.C. Machiels J.-P. Arkenau H.-T. Plummer R. Jones R.H. Nielsen D. Windfeld K. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1–2 trial Lancet Oncol. 2019 20 383 393 10.1016/S1470-2045(18)30859-3 30745090

143. Skidmore L. Sakamuri S. Knudsen N.A. Hewet A.G. Milutinovic S. Barkho W. Biroc S.L. Kirtley J. Marsden R. Storey K. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers Mol. Cancer Ther. 2020 19 1833 1843 10.1158/1535-7163.MCT-19-1004 32669315

144. Lopez D.M. Barve M. Wang J. Bullock A.J. Pectasides E. Vaishampayan U. Spira A.I. Ulahannan S. Patnaik A. Sanborn R.E. Abstract B005: A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors Mol. Cancer Ther. 2019 18 B005 10.1158/1535-7163.Targ-19-b005

145. Maclaren A.P. Levin N. Lowman H. Abstract 835: TRPH-222, a novel anti-CD22 antibody drug conjugate (ADC), has significant anti-tumor activity in NHL xenografts and reduces B cells in monkeys Cancer Res. 2018 78 835 10.1158/1538-7445.AM2018-835

146. Radford J. Kahl B.S. Hamadani M. Carlo-Stella C. Caimi P. Ardeshna K.M. Feingold J. He S. Reid E. Solh M. Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Blood 2018 132 398 10.1182/blood-2018-99-116081

147. Hamadani M. Collins G.P. Samaniego F. Spira A.I. Davies A. Radford J. Caimi P. Menne T. Boni J. Cruz H. Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma Blood 2018 132 928 10.1182/blood-2018-99-118198

148. Anderson M.G. Falls H.D. Mitten M.J. Oleksijew A. Vaidya K.S. Boghaert E.R. Gao W. Palma J.P. Cao D. Chia P.-L. Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate Mol. Cancer Ther. 2020 10.1158/1535-7163.MCT-20-0149 32847977

149. Abu-Yousif A.O. Bannerman B.M. Cvet D. Gallery M. Ganno M.L. Smith M.D. Lai K.C. Keating T.A. Bolleddula J. Stringer B. Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies Mol. Cancer Ther. 2018 17 B120 10.1158/1535-7163.Targ-17-b120

150. Shah N.N. Krishnan A.Y. Shah N.D. Burke J.M. Melear J.M. Spira A.I. Popplewell L.L. Andreadis C.B. Chhabra S. Sharman J.P. Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies Blood 2019 134 5329 10.1182/blood-2019-122754

151. Li X. Abrahams C. Zhou S. Krimm S. Henningsen R. Stephenson H. Hanson J. Masikat M.R. Bajjuri K. Heibeck T. Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer Cancer Res. 2018 78 1782 10.1158/1538-7445.AM2018-1782 PMC9890132 36459691

152. Yang C.-Y. Wang L. Sun X. Tang M. Quan H.-T. Zhang L.-S. Lou L.-G. Gou S.-H. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models Acta Pharmacol. Sin. 2019 40 971 979 10.1038/s41401-018-0198-0 30643210 PMC6786420

153. García-Alonso S. Ocaña A. Pandiella A. Resistance to Antibody-Drug Conjugates Cancer Res. 2018 78 2159 10.1158/0008-5472.CAN-17-3671 29653942

154. Loganzo F. Tan X. Sung M. Jin G. Myers J.S. Melamud E. Wang F. Diesl V. Follettie M.T. Musto S. Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments Mol. Cancer Ther. 2015 14 952 963 10.1158/1535-7163.MCT-14-0862 25646013

155. Al-Rohil R.N. Torres-Cabala C.A. Patel A. Tetzlaff M.T. Ivan D. Nagarajan P. Curry J.L. Miranda R.N. Duvic M. Prieto V.G. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding J. Cutan. Pathol. 2016 43 1161 1166 10.1111/cup.12797 27531242

156. Phillips G.D.L. Fields C.T. Li G. Dowbenko D. Schaefer G. Miller K. Andre F. Burris H.A. Albain K.S. Harbeck N. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2014 20 456 10.1158/1078-0432.CCR-13-0358 24097864

157. Sung M. Golas J. Wang F. King L. Myers J. Rosfjord E. Lucas J. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) Mol. Cancer Ther. 2018 17 243 253 10.1158/1535-7163.MCT-17-0403 29054985

158. Ríos-Luci C. García-Alonso S. Díaz-Rodríguez E. Nadal-Serrano M. Arribas J. Ocaña A. Pandiella A. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity Cancer Res. 2017 77 4639 10.1158/0008-5472.CAN-16-3127 28687619

159. Kinneer K. Meekin J. Tiberghien A.C. Tai Y.-T. Phipps S. Kiefer C.M. Rebelatto M.C. Dimasi N. Moriarty A. Papadopoulos K.P. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2018 24 6570 10.1158/1078-0432.CCR-18-1300 30131388

160. Hunter F.W. Barker H.R. Lipert B. Rothé F. Gebhart G. Piccart-Gebhart M.J. Sotiriou C. Jamieson S.M.F. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer Br. J. Cancer 2020 122 603 612 10.1038/s41416-019-0635-y 31839676 PMC7054312

161. Collins D.M. Bossenmaier B. Kollmorgen G. Niederfellner G. Acquired Resistance to Antibody-Drug Conjugates Cancers 2019 11 394 10.3390/cancers11030394 30897808 PMC6468698

162. Haag P. Viktorsson K. Lindberg M.L. Kanter L. Lewensohn R. Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML Exp. Hematol. 2009 37 755 766 10.1016/j.exphem.2009.03.002 19463775

163. Walter R.B. Raden B.W. Cronk M.R. Bernstein I.D. Appelbaum F.R. Banker D.E. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood 2004 103 4276 4284 10.1182/blood-2003-11-3825 14962898

164. Loganzo F. Sung M. Gerber H.-P. Mechanisms of Resistance to Antibody–Drug Conjugates Mol. Cancer Ther. 2016 15 2825 2834 10.1158/1535-7163.MCT-16-0408 27780876

165. Kovtun Y.V. Audette C.A. Mayo M.F. Jones G.E. Doherty H. Maloney E.K. Erickson H.K. Sun X. Wilhelm S. Ab O. Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance Cancer Res. 2010 70 2528 2537 10.1158/0008-5472.CAN-09-3546 20197459

166. Kaitin K.I. Dimasi J.A. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 Clin. Pharmacol. Ther. 2010 89 183 10.1038/clpt.2010.286 21191382

167. DiMasi J.A. Grabowski H.G. The cost of biopharmaceutical R&D: Is biotech different? Manag. Decis. Econ. 2007 28 469 479 10.1002/mde.1360

168. Dammes N. Peer D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities Theranostics 2020 10 938 955 10.7150/thno.37443 31903161 PMC6929980

169. Carmon K.S. Azhdarinia A. Application of Immuno-PET in Antibody–Drug Conjugate Development Mol. Imaging 2018 17 1536012118801223 10.1177/1536012118801223 30370812 PMC6207972

170. Van Dongen G.A.M.S. Visser G.W.M. Lub-De Hooge M.N. De Vries E.G. Perk L.R. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications Oncologist 2007 12 1379 1389 10.1634/theoncologist.12-12-1379 18165614

171. Wei W. Rosenkrans Z.T. Liu J. Huang G. Luo Q.-Y. Cai W. ImmunoPET: Concept, Design, and Applications Chem. Rev. 2020 120 3787 3851 10.1021/acs.chemrev.9b00738 32202104 PMC7265988

172. Kang L. Jiang D. Ehlerding E.B. Barnhart T.E. Ni D. Engle J.W. Wang R. Huang P. Xu X. Cai W. Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models Mol. Pharm. 2018 15 1627 1634 10.1021/acs.molpharmaceut.7b01168 29537283 PMC5920523

173. Wang R. Li L. Zhang S. Li Y. Wang X. Miao Q. Zhen Y. A novel enediyne-integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas Mol. Oncol. 2018 12 339 355 10.1002/1878-0261.12166 29316337 PMC5830626

174. Wang R. Li L. Duan A. Li Y. Liu X. Miao Q. Gong J. Zhen Y. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma Cancer Lett. 2019 448 84 93 10.1016/j.canlet.2019.02.002 30742941

175. Gong J. Guo F. Cheng W. Fan H. Miao Q. Yang J. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models Artif. Cells Nanomed. Biotechnol. 2020 48 408 414 10.1080/21691401.2019.1709857 31913714

176. Glynne-Jones E. Harper M.E. Seery L.T. James R. Anglin I. Morgan H.E. Taylor K.M. Gee J.M. Nicholson R.I. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence Int. J. Cancer 2001 94 178 184 10.1002/ijc.1450 11668495

177. Hubert R.S. Vivanco I. Chen E. Rastegar S. Leong K. Mitchell S.C. Madraswala R. Zhou Y. Kuo J. Raitano A.B. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors Proc. Natl. Acad. Sci. USA 1999 96 14523 10.1073/pnas.96.25.14523 10588738 PMC24469

178. Williams S. Ogasawara A. Tinianow J. Flores J. Kan D. Lau J. Go M. Vanderbilt A. Gill H. Miao L. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1 Oncotarget 2016 7 25103 25112 10.18632/oncotarget.8390 27029064 PMC5041891

179. Servais E.L. Colovos C. Rodriguez L. Bograd A.J. Nitadori J.-I. Sima C. Rusch V.W. Sadelain M. Adusumilli P.S. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012 18 2478 2489 10.1158/1078-0432.CCR-11-2614 22371455 PMC3759995

180. Lamberts L.E. Menke-van Der Houven van Oordt C.W. Ter Weele E.J. Bensch F. Smeenk M.M. Voortman J. Hoekstra O.S. Williams S.P. Fine B.M. Maslyar D. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016 22 1642 10.1158/1078-0432.CCR-15-1272 26589435

181. Azhdarinia A. Voss J. Ghosh S.C. Simien J.A. Hernandez Vargas S. Cui J. Yu W.A. Liu Q. Carmon K.S. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates Mol. Pharm. 2018 15 2448 2454 10.1021/acs.molpharmaceut.8b00275 29718672

182. Morgan R.G. Mortensson E. Williams A.C. Targeting LGR5 in Colorectal Cancer: Therapeutic gold or too plastic? Br. J. Cancer 2018 118 1410 1418 10.1038/s41416-018-0118-6 29844449 PMC5988707

183. Gong X. Azhdarinia A. Ghosh S.C. Xiong W. An Z. Liu Q. Carmon K.S. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence Mol. Cancer Ther. 2016 15 1580 1590 10.1158/1535-7163.MCT-16-0114 27207778

184. Scott A.M. Geleick D. Rubira M. Clarke K. Nice E.C. Smyth F.E. Stockert E. Richards E.C. Carr F.J. Harris W.J. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors Cancer Res. 2000 60 3254 10.1038/35015728 10866319

185. Boghaert E. Sridharan L. Armellino D.C. Khandke K. Dijoseph J. Kunz A. Dougher M.M. Jiang F. Kalyandrug L. Hamann P. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-Acetyl gamma calicheamicin dimethyl hydrazide targets lewisy and eliminates Lewis(y)-positive human carcinoma cells and xenografts Clin. Cancer Res. 2004 10 4538 4549 10.1158/1078-0432.CCR-04-0037 15240546

186. Herbertson R.A. Tebbutt N.C. Lee F.-T. Macfarlane D.J. Chappell B. Micallef N. Lee S.-T. Saunder T. Hopkins W. Smyth F.E. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009 15 6709 10.1158/1078-0432.CCR-09-0536 PMC6944432 19825951

187. Scott A.M. Tebbutt N. Lee F.-T. Cavicchiolo T. Liu Z. Gill S. Poon A.M.T. Hopkins W. Smyth F.E. Murone C. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007 13 3286 10.1158/1078-0432.CCR-07-0284 17545534

188. Gebhart G. Lamberts L.E. Wimana Z. Garcia C. Emonts P. Ameye L. Stroobants S. Huizing M. Aftimos P. Tol J. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial Ann. Oncol. 2016 27 619 624 10.1093/annonc/mdv577 26598545